Reference(s)
Click here to return to the Reference Table

Descriptor: Met expression


Acute Myelogenous Leukemia

Reference Number: 1735
McGee SF, Kornblau SM, Qiu Y, Look AT, Zhang N, Yoo SY, Coombes KR, Kentsis A Biological properties of ligand-dependent activation of the MET receptor kinase in acute myeloid leukemia. Leukemia. 29, 1218-21 (2015)
PubMed link      E-mail link

Adult T Cell Leukemia

Reference Number: 180
Imaizumi, Y. et al. Expression of the c-Met proto-oncogene and its possible involvement in liver invasion in adult T-cell leukemia. Clin Cancer Res 9, 181-7 (2003).
PubMed link      E-mail link

Reference Number: 516
Choi YL, Tsukasaki K, O'Neill MC, Yamada Y, Onimaru Y, Matsumoto K, Ohashi J, Yamashita Y, Tsutsumi S, Kaneda R, Takada S, Aburatani H, Kamihira S, Nakamura T, Tomonaga M, Mano H. A genomic analysis of adult T-cell leukemia. Oncogene. 26, 1245-55 (2007)
PubMed link      E-mail link

Reference Number: 690
Onimaru Y, Tsukasaki K, Murata K, Imaizumi Y, Choi YL, Hasegawa H, Sugahara K, Yamada Y, Hayashi T, Nakashima M, Taguchi T, Mano H, Kamihira S, Tomonaga M. Autocrine and/or paracrine growth of aggressive ATLL cells caused by HGF and c-Met. Int J Oncol. 33, 697-703 (2008)
PubMed link      E-mail link

Bladder

Reference Number: 3
Cheng, H. L. et al. Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. J Clin Oncol 20, 1544-50. (2002).
PubMed link      E-mail link

Reference Number: 455
Cheng HL, Liu HS, Lin YJ, Chen HH, Hsu PY, Chang TY, Ho CL, Tzai TS, Chow NH. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. Br J Cancer. 92, 1906-14 (2005)
PubMed link      E-mail link

Reference Number: 549
Koga F, Tsutsumi S, Neckers LM. Low dose geldanamycin inhibits hepatocyte growth factor and hypoxia-stimulated invasion of cancer cells. Cell Cycle. 6, 1393-402 (2007)
PubMed link      E-mail link

Reference Number: 591
Wu TF, Wu H, Wang YW, Chang TY, Chan SH, Lin YP, Liu HS, Chow NH. Prohibitin in the pathogenesis of transitional cell bladder cancer. Anticancer Res. 27, 895-900 (2007)
PubMed link      E-mail link

Reference Number: 592
Wang P, Nishitani MA, Tanimoto S, Kishimoto T, Fukumori T, Takahashi M, Kanayama HO. Bladder cancer cell invasion is enhanced by cross-talk with fibroblasts through hepatocyte growth factor. Urology. 69, 780-4 (2007)
PubMed link      E-mail link

Reference Number: 593
Todeschini AR, Dos Santos JN, Handa K, Hakomori SI. Ganglioside GM2-tetraspanin CD82 complex inhibits met and its cross-talk with integrins, providing a basis for control of cell motility through glycosynapse. J Biol Chem. 282, 8123-33 (2007)
PubMed link      E-mail link

Reference Number: 627
Compérat E, Roupret M, Chartier-Kastler E, Bitker MO, Richard F, Camparo P, Capron F, Cussenot O. Prognostic value of MET, RON and histoprognostic factors for urothelial carcinoma in the upper urinary tract. J Urol. 179, 868-72 (2008)
PubMed link      E-mail link

Reference Number: 806
Eissa S, Swellam M, Labib RA, El-Zayat T, El Ahmady O. A panel of angiogenic factors for early bladder cancer detection: enzyme immunoassay and Western blot. J Urol. 181, 1353-60 (2009)
PubMed link      E-mail link

Reference Number: 808
Miyata Y, Sagara Y, Kanda S, Hayashi T, Kanetake H. Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin. Hum Pathol. 40, 496-504 (2009)
PubMed link      E-mail link

Reference Number: 853
Bhuvaneswari R, Gan YY, Lucky SS, Chin WW, Ali SM, Soo KC, Olivo M. Molecular profiling of angiogenesis in hypericin mediated photodynamic therapy. Mol Cancer. 7, 56 (2008)
PubMed link      E-mail link

Reference Number: 854
Todeschini AR, Dos Santos JN, Handa K, Hakomori SI. Ganglioside GM2/GM3 complex affixed on silica nanospheres strongly inhibits cell motility through CD82/cMet-mediated pathway. Proc Natl Acad Sci U S A. 105, 1925-30 (2008)
PubMed link      E-mail link

Reference Number: 1122
Yeh CY, Shin SM, Yeh HH, Wu TJ, Shin JW, Chang TY, Raghavaraju G, Lee CT, Chiang JH, Tseng VS, Lee YC, Shen CH, Chow NH, Liu HS. Transcriptional activation of the Axl and PDGFR-a by c-Met through a ras- and Src-independent mechanism in human bladder cancer. BMC Cancer. 11, 139 (2011)
PubMed link      E-mail link

Reference Number: 1392
Hofner T1, Macher-Goeppinger S, Klein C, Rigo-Watermeier T, Eisen C, Pahernik S, Hohenfellner M, Trumpp A, Sprick MR. Development and characteristics of preclinical experimental models for the research of rare neuroendocrine bladder cancer. J Urol. 190, 2263-70 (2013)
PubMed link      E-mail link

Reference Number: 1393
Majumdar S1, Gong EM, Di Vizio D, Dreyfuss J, Degraff DJ, Hager MH, Park PJ, Bellmunt J, Matusik RJ, Rosenberg JE, Adam RM. Loss of Sh3gl2/endophilin A1 is a common event in urothelial carcinoma that promotes malignant behavior. Neoplasia. 15, 749-60 (2013)
PubMed link      E-mail link

Reference Number: 1431
Xu X1, Chen H, Lin Y, Hu Z, Mao Y, Wu J, Xu X, Zhu Y, Li S, Zheng X, Xie L. MicroRNA-409-3p inhibits migration and invasion of bladder cancer cells via targeting c-Met. Mol Cells. 36, 62-8 (2013)
PubMed link      E-mail link

Reference Number: 1480
Kluth M, Reynolds K, Rink M, Chun F, Dahlem R, Fisch M, Höppner W, Wagner W, Doh O, Terracciano L, Simon R, Sauter G, Minner S. Reduced membranous MET expression is linked to bladder cancer progression. Cancer Genet. 207, 147-52 (2014)
PubMed link      E-mail link

Reference Number: 1744
Chiyomaru T, Seki N, Inoguchi S, Ishihara T, Mataki H, Matsushita R, Goto Y, Nishikawa R, Tatarano S, Itesako T, Nakagawa M, Enokida H. Dual regulation of receptor tyrosine kinase genes EGFR and c-Met by the tumor-suppressive microRNA-23b/27b cluster in bladder cancer. Int J Oncol. 46, 487-96 (2015)
PubMed link      E-mail link

Reference Number: 1746
Matsumoto R, Tsuda M, Wang L, Maishi N, Abe T, Kimura T, Tanino M, Nishihara H, Hida K, Ohba Y, Shinohara N, Nonomura K, Tanaka S. Adaptor protein CRK induces epithelial-mesenchymal transition and metastasis of bladder cancer cells through HGF/c-Met feedback loop. Cancer Sci. 106, 709-17 (2015)
PubMed link      E-mail link

Reference Number: 1834
Kim YW, Yun SJ, Jeong P, Kim SK, Kim SY, Yan C, Seo SP, Lee SK, Kim J, Kim WJ The c-MET Network as Novel Prognostic Marker for Predicting Bladder Cancer Patients with an Increased Risk of Developing Aggressive Disease. PLoS One. 10, e0134552 (2015)
PubMed link      E-mail link

Breast

Reference Number: 6
Edakuni, G., Sasatomi, E., Satoh, T., Tokunaga, O. & Miyazaki, K. Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma. Pathol Int 51, 172-8. (2001).
PubMed link      E-mail link

Reference Number: 7
Jin, L. et al. Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer 79, 749-60. (1997).
PubMed link      E-mail link

Reference Number: 8
Kang, J. Y. et al. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 63, 1101-5 (2003).
PubMed link      E-mail link

Reference Number: 9
Nagy, J. et al. Hepatocyte growth factor/scatter factor expression and c-met in primary breast cancer. Surg Oncol 5, 15-21. (1996).
PubMed link      E-mail link

Reference Number: 10
Tuck, A. B., Park, M., Sterns, E. E., Boag, A. & Elliott, B. E. Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Am J Pathol 148, 225-32 (1996).
PubMed link      E-mail link

Reference Number: 13
Beviglia, L., Matsumoto, K., Lin, C. S., Ziober, B. L. & Kramer, R. H. Expression of the c-Met/HGF receptor in human breast carcinoma: correlation with tumor progression. Int J Cancer 74, 301-9. (1997).
PubMed link      E-mail link

Reference Number: 14
Camp, R. L., Rimm, E. B. & Rimm, D. L. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 86, 2259-65. (1999).
PubMed link      E-mail link

Reference Number: 16
Tsarfaty, I. et al. Alteration of Met protooncogene product expression and prognosis in breast carcinomas. Anal Quant Cytol Histol 21, 397-408. (1999).
PubMed link      E-mail link

Reference Number: 232
Tolgay Ocal, I, Dolled-Filhart, M, D'Aquila, TG, Camp, RL, & Rimm, DL.  Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer 97:1841-8 (2003).
PubMed link      E-mail link

Reference Number: 233
Greenberg, R, Schwartz, I, Skornick Y, & Kaplan O. Detection of hepatocyte growth factor/scatter factor receptor (c-Met) in axillary drainage after operations for breast cancer using reverse transcriptase-polymerase chain reaction. Breast Cancer Res 5:71-76 (2003).
PubMed link      E-mail link

Reference Number: 234
Greenberg R, Barnea Y, Schneebaum S, Kashtan H, Kaplan O, Skornik Y. Detection of hepatocyte growth factor/scatter factor receptor (c-Met) and MUC1 from the axillary fluid drainage in patients after breast cancer surgery. Isr Med Assoc J 5:649-52 (2003).
PubMed link      E-mail link

Reference Number: 237
Parr C, Watkins G, Mansel RE, Jiang WG. The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res 10:202-11 (2004).
PubMed link      E-mail link

Reference Number: 306
Lee WY, Su WC, Lin PW, Guo HR, Chang TW, Chen HH. Expression of S100A4 and Met: potential predictors for metastasis and survival in early-stage breast cancer. Oncology 66, 429-38 (2004)
PubMed link      E-mail link

Reference Number: 307
Jones BA, Kasl SV, Howe CL, Lachman M, Dubrow R, Curnen MM, Soler-Vila H, Beeghly A, Duan F, Owens P. African-American/White differences in breast carcinoma: p53 alterations and other tumor characteristics. Cancer 101, 1293-301 (2004)
PubMed link      E-mail link

Reference Number: 331
Lee WY, Chen HH, Chow NH, Su WC, Lin PW, Guo HR. Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. Clin Cancer Res11, 2222-8 (2005)
PubMed link      E-mail link

Reference Number: 332
Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, Lindemann K, Salanti G, Richter T, Knudsen B, Vande Woude GF, Harbeck N. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer  113, 678-82 (2005)
PubMed link      E-mail link

Reference Number: 346
Welm AL, Kim S, Welm BE, Bishop JM. MET and MYC cooperate in mammary tumorigenesis. Proc Natl Acad Sci U S A. 102, 4324-9 (2005)
PubMed link      E-mail link

Reference Number: 358
Khoury H, Naujokas MA, Zuo D, Sangwan V, Frigault MM, Petkiewicz S, Dankort DL, Muller WJ, Park M. HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion. Mol Biol Cell. 16 550-61(2005)
PubMed link      E-mail link

Reference Number: 365
Bertotti A, Comoglio PM, Trusolino L. Beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis. Cancer Res. 65, 10674-9 (2005)
PubMed link      E-mail link

Reference Number: 367
Singletary K, Ellington A. Genistein suppresses proliferation and MET oncogene expression and induces EGR-1 tumor suppressor expression in immortalized human breast epithelial cells. Anticancer Res. 26, 1039-48 (2006)
PubMed link      E-mail link

Reference Number: 368
Smolen GA, Muir B, Mohapatra G, Barmettler A, Kim WJ, Rivera MN, Haserlat SM, Okimoto RA, Kwak E, Dahiya S, Garber JE, Bell DW, Sgroi DC, Chin L, Deng CX, Haber DA. Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis. Cancer Res. 66, 3452-5 (2006)
PubMed link      E-mail link

Reference Number: 404
Bigelow RL, Cardelli JA. The green tea catechins, (-)-Epigallocatechin-3-gallate (EGCG) and (-)-Epicatechin-3-gallate (ECG), inhibit HGF/Met signaling in immortalized and tumorigenic breast epithelial cells. Oncogene. 25, 1922-30 (2006)
PubMed link      E-mail link

Reference Number: 461
Chen CC, Hou MF, Wang JY, Chang TW, Lai DY, Chen YF, Hung SY, Lin SR. Simultaneous detection of multiple mRNA markers CK19, CEA, c-Met, Her2/neu and hMAM with membrane array, an innovative technique with a great potential for breast cancer diagnosis. Cancer Lett. 2005 Nov 11; [Epub ahead of print]
PubMed link      E-mail link

Reference Number: 462
Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adelaide J, Cervera N, Fekairi S, Xerri L, Jacquemier J, Birnbaum D, Bertucci F. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene. 25, 2273-84 (2006)
PubMed link      E-mail link

Reference Number: 526
Pozner-Moulis S, Cregger M, Camp RL, Rimm DL. Antibody validation by quantitative analysis of protein expression using expression of Met in breast cancer as a model. Lab Invest. 87, 251-60 (2007)
PubMed link      E-mail link

Reference Number: 527
Götte M, Kersting C, Radke I, Kiesel L, Wülfing P. An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. Breast Cancer Res. 9, R8 (2007)
PubMed link      E-mail link

Reference Number: 534
Garcia S, Dalès JP, Jacquemier J, Charafe-Jauffret E, Birnbaum D, Andrac-Meyer L, Lavaut MN, Allasia C, Carpentier-Meunier S, Bonnier P, Charpin-Taranger C. c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays. Br J Cancer. 96, 329-35 (2007)
PubMed link      E-mail link

Reference Number: 535
Hiscox S, Jordan NJ, Jiang W, Harper M, McClelland R, Smith C, Nicholson RI. Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions. Endocr Relat Cancer. 13, 1085-99 (2006)
PubMed link      E-mail link

Reference Number: 544
Matteucci E, Ridolfi E, Desiderio MA. Hepatocyte growth factor differently influences Met-E-cadherin phosphorylation and downstream signaling pathway in two models of breast cells. Cell Mol Life Sci. 63, 2016-26 (2006)
PubMed link      E-mail link

Reference Number: 548
Chen HH, Su WC, Lin PW, Guo HR, Lee WY. Hypoxia-inducible factor-1alpha correlates with MET and metastasis in node-negative breast cancer. Breast Cancer Res Treat. 103, 167-75 (2007)
PubMed link      E-mail link

Reference Number: 555
Lindemann K, Resau J, Nährig J, Kort E, Leeser B, Annecke K, Welk A, Schäfer J, Vande Woude GF, Lengyel E, Harbeck N. Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue. Histopathology. 51, 54-62 (2007)
PubMed link      E-mail link

Reference Number: 556
Garcia S, Dalès JP, Charafe-Jauffret E, Carpentier-Meunier S, Andrac-Meyer L, Jacquemier J, Andonian C, Lavaut MN, Allasia C, Bonnier P, Charpin C. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Hum Pathol. 38, 830-41 (2007)
PubMed link      E-mail link

Reference Number: 562
Cheng N, Chytil A, Shyr Y, Joly A, Moses HL. Enhanced hepatocyte growth factor signaling by type II transforming growth factor-beta receptor knockout fibroblasts promotes mammary tumorigenesis. Cancer Res. 67, 4869-77 (2007)
PubMed link      E-mail link

Reference Number: 574
Götte M, Kersting C, Radke I, Kiesel L, Wülfing P. An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. Breast Cancer Res. 9, R8 (2007)
PubMed link      E-mail link

Reference Number: 575
Pozner-Moulis S, Pappas DJ, Rimm DL. Met, the hepatocyte growth factor receptor, localizes to the nucleus in cells at low density. Cancer Res. 66, 7976-82 (2006)
PubMed link      E-mail link

Reference Number: 576
Garcia S, Dales JP, Charafe-Jauffret E, Carpentier-Meunier S, Andrac-Meyer L, Jacquemier J, Andonian C, Lavaut MN, Allasia C, Bonnier P, Charpin C. Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesis. Int J Oncol. 31, 49-58 (2007)
PubMed link      E-mail link

Reference Number: 594
Shattuck DL, Miller JK, Laederich M, Funes M, Petersen H, Carraway KL 3rd, Sweeney C. LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy. Mol Cell Biol. 27, 1934-46 (2007)
PubMed link      E-mail link

Reference Number: 610
Lee WJ, Chen WK, Wang CJ, Lin WL, Tseng TH. Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells. Toxicol Appl Pharmacol. 226, 178-91 (2007)
PubMed link      E-mail link

Reference Number: 614
Morozov VM, Massoll NA, Vladimirova OV, Maul GG, Ishov AM. Regulation of c-met expression by transcription repressor Daxx. Oncogene. 27, 2177-86 (2008)
PubMed link      E-mail link

Reference Number: 619
Klosek SK, Nakashiro K, Hara S, Goda H, Hasegawa H, Hamakawa H. CD151 regulates HGF-stimulated morphogenesis of human breast cancer cells. Biochem Biophys Res Commun. 379, 1097-100 (2009)
PubMed link      E-mail link

Reference Number: 626
Furlan A, Vercamer C, Desbiens X, Pourtier A. Ets-1 triggers and orchestrates the malignant phenotype of mammary cancer cells within their matrix environment. J Cell Physiol. 215, 782-93 (2008)
PubMed link      E-mail link

Reference Number: 636
Leibowitz-Amit R, Tsarfaty G, Abargil Y, Yerushalmi GM, Horev J, Tsarfaty I. Mimp, a mitochondrial carrier homologue, inhibits Met-HGF/SF-induced scattering and tumorigenicity by altering Met-HGF/SF signaling pathways. Cancer Res. 66, 8687-97 (2006)
PubMed link      E-mail link

Reference Number: 643
Xu H, Washington S, Verderame MF, Manni A. Role of non-receptor and receptor tyrosine kinases (TKs) in the antitumor action of alpha-difluoromethylornithine (DFMO) in breast cancer cells. Breast Cancer Res Treat. 112, 255-61 (2008)
PubMed link      E-mail link

Reference Number: 649
Shattuck DL, Miller JK, Carraway KL 3rd, Sweeney C. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res. 68, 1471-7 (2008)
PubMed link      E-mail link

Reference Number: 652
Mueller KL, Hunter LA, Ethier SP, Boerner JL. Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res. 68, 3314-22 (2008)
PubMed link      E-mail link

Reference Number: 676
Syed DN, Afaq F, Sarfaraz S, Khan N, Kedlaya R, Setaluri V, Mukhtar H. Delphinidin inhibits cell proliferation and invasion via modulation of Met receptor phosphorylation. Toxicol Appl Pharmacol. 231, 52-60 (2008)
PubMed link      E-mail link

Reference Number: 685
Graveel CR, DeGroot JD, Su Y, Koeman J, Dykema K, Leung S, Snider J, Davies SR, Swiatek PJ, Cottingham S, Watson MA, Ellis MJ, Sigler RE, Furge KA, Vande Woude GF. Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci U S A. 106, 12909-14 (2009)
PubMed link      E-mail link

Reference Number: 712
Lindemann K, Harbeck N, Lengyel E, Resau JH. A special key for unlocking the door to targeted therapies of breast cancer. ScientificWorldJournal. 8, 905-8 (2008)
PubMed link      E-mail link

Reference Number: 716
Ponzo MG, Lesurf R, Petkiewicz S, O'Malley FP, Pinnaduwage D, Andrulis IL, Bull SB, Chughtai N, Zuo D, Souleimanova M, Germain D, Omeroglu A, Cardiff RD, Hallett M, Park M. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci U S A. 106, 12903-8 (2009)
PubMed link      E-mail link

Reference Number: 804
Finkbeiner MR, Astanehe A, To K, Fotovati A, Davies AH, Zhao Y, Jiang H, Stratford AL, Shadeo A, Boccaccio C, Comoglio P, Mertens PR, Eirew P, Raouf A, Eaves CJ, Dunn SE. Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells. Oncogene. 28, 1421-31 (2009)
PubMed link      E-mail link

Reference Number: 805
Carracedo A, Egervari K, Salido M, Rojo F, Corominas JM, Arumi M, Corzo C, Tusquets I, Espinet B, Rovira A, Albanell J, Szollosi Z, Serrano S, Solé F. FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumors. Breast Cancer Res. 11, 402 (2009)
PubMed link      E-mail link

Reference Number: 839
Previdi S, Maroni P, Matteucci E, Broggini M, Bendinelli P, Desiderio MA. Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and beta-catenin/Wnt pathways. Eur J Cancer. 46, 1679-91 (2010)
PubMed link      E-mail link

Reference Number: 847
Taraseviciute A, Vincent BT, Schedin P, Jones PL. Quantitative analysis of three-dimensional human mammary epithelial tissue architecture reveals a role for tenascin-C in regulating c-met function. Am J Pathol. 176, 827-38 (2010)
PubMed link      E-mail link

Reference Number: 922
Castro NE, Lange CA. Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells. Breast Cancer Res. 12, R60 (2010)
PubMed link      E-mail link

Reference Number: 965
Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, Kaufman D, Dekoning T, Eagleson B, Buchanan SG, Vande Woude GF. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 70, 6880-90 (2010)
PubMed link      E-mail link

Reference Number: 983
Tsarfaty I, Alvord WG, Resau JH, Altstock RT, Lidereau R, Bieche I, Bertrand F, Horev J, Klabansky RL, Keydar I, Vande Woude GF. Alteration of Met protooncogene product expression and prognosis in breast carcinomas. Anal Quant Cytol Histol. 21, 397-408 (1999)
PubMed link      E-mail link

Reference Number: 1018
Ronen D, Altstock RT, Firon M, Mittelman L, Sobe T, Resau JH, Vande Woude GF, Tsarfaty I. Met-HGF/SF mediates growth arrest and differentiation in T47D breast cancer cells. Cell Growth Differ. 10, 131-40 (1999)
PubMed link      E-mail link

Reference Number: 1160
Xu K, Usary J, Kousis PC, Prat A, Wang DY, Adams JR, Wang W, Loch AJ, Deng T, Zhao W, Cardiff RD, Yoon K, Gaiano N, Ling V, Beyene J, Zacksenhaus E, Gridley T, Leong WL, Guidos CJ, Perou CM, Egan SE. Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancer. Cancer Cell. 21, 626-41 (2012)
PubMed link      E-mail link

Reference Number: 1177
Cooke VG, LeBleu VS, Keskin D, Khan Z, O'Connell JT, Teng Y, Duncan MB, Xie L, Maeda G, Vong S, Sugimoto H, Rocha RM, Damascena A, Brentani RR, Kalluri R. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell. 21, 66-81 (2012)
PubMed link      E-mail link

Reference Number: 1238
Cazet A, Bobowski M, Rombouts Y, Lefebvre J, Steenackers A, Popa I, Guérardel Y, Le Bourhis X, Tulasne D, Delannoy P. The ganglioside G(D2) induces the constitutive activation of c-Met in MDA-MB-231 breast cancer cells expressing the G(D3) synthase. Glycobiology. 22, 806-16 (2012)
PubMed link      E-mail link

Reference Number: 1243
Accornero P, Miretti S, Bersani F, Quaglino E, Martignani E, Baratta M. Met receptor acts uniquely for survival and morphogenesis of EGFR-dependent normal mammary epithelial and cancer cells. PLoS One. 7, e44982 (2012)
PubMed link      E-mail link

Reference Number: 1267
Gastaldi S, Sassi F, Accornero P, Torti D, Galimi F, Migliardi G, Molyneux G, Perera T, Comoglio PM, Boccaccio C, Smalley MJ, Bertotti A, Trusolino L. Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer. Oncogene. 32, 1428-40 (2013)
PubMed link      E-mail link

Reference Number: 1432
Paulson AK1, Linklater ES, Berghuis BD, App CA, Oostendorp LD, Paulson JE, Pettinga JE, Melnik MK, Vande Woude GF, Graveel CR. MET and ERBB2 are coexpressed in ERBB2 breast cancer and contribute to innate resistance. Mol Cancer Res. 11, 1112-21 (2013)
PubMed link      E-mail link

Reference Number: 1449
Inanc M1, Ozkan M, Karaca H, Berk V, Bozkurt O, Duran AO, Ozaslan E, Akgun H, Tekelioglu F, Elmali F. Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer. Med Oncol. 31, 801 (2014)
PubMed link      E-mail link

Reference Number: 1467
Ho-Yen CM, Green AR, Rakha EA, Brentnall AR, Ellis IO, Kermorgant S, Jones JL. C-Met in invasive breast cancer: is there a relationship with the basal-like subtype? Cancer. 120, 163-71 (2014)
PubMed link      E-mail link

Reference Number: 1522
Kim YJ, Choi JS, Seo J, Song JY, Lee SE, Kwon MJ, Kwon MJ, Kundu J, Jung K, Oh E, Shin YK, Choi YL. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer. Int J Cancer. 134, 2424-36 (2014)
PubMed link      E-mail link

Reference Number: 1524
Zagouri F, Brandstetter A, Moussiolis D, Chrysikos D, Dimitrakakis C, Tsigginou A, Marinopoulos S, Zografos GC, Sergentanis TN, Dimopoulos MA, Filipits M. Low protein expression of MET in ER-positive and HER2-positive breast cancer. Anticancer Res. 34, 1227-31 (2014)
PubMed link      E-mail link

Reference Number: 1525
Laser-Azogui A, Diamant-Levi T, Israeli S, Roytman Y, Tsarfaty I. Met-induced membrane blebbing leads to amoeboid cell motility and invasion. Oncogene. 33, 1788-98 (2014)
PubMed link      E-mail link

Reference Number: 1542
Casbas-Hernandez P, D'Arcy M, Roman-Perez E, Brauer HA, McNaughton K, Miller SM, Chhetri RK, Oldenburg AL, Fleming JM, Amos KD, Makowski L, Troester MA. Role of HGF in epithelial-stromal cell interactions during progression from benign breast disease to ductal carcinoma in situ. Breast Cancer Res. 15, R82 (2013)
PubMed link      E-mail link

Reference Number: 1557
Basilico C, Hultberg A, Blanchetot C, de Jonge N, Festjens E, Hanssens V, Osepa SI, De Boeck G, Mira A, Cazzanti M, Morello V, Dreier T, Saunders M, de Haard H, Michieli P. Four individually druggable MET hotspots mediate HGF-driven tumor progression. J Clin Invest. 124, 3172-86 (2014)
PubMed link      E-mail link

Reference Number: 1601
Feng Y, Pan TC, Pant DK, Chakrabarti KR, Alvarez JV, Ruth JR, Chodosh LA. SPSB1 promotes breast cancer recurrence by potentiating c-MET signaling. Cancer Discov. 4, 790-803 (2014)
PubMed link      E-mail link

Reference Number: 1630
Eterno V, Zambelli A, Pavesi L, Villani L, Zanini V, Petrolo G, Manera S, Tuscano A, Amato A. Adipose-derived Mesenchymal Stem Cells (ASCs) may favour breast cancer recurrence via HGF/c-Met signaling. Oncotarget. 5, 613-33 (2014)
PubMed link      E-mail link

Reference Number: 1659
Zhang S, Chung WC, Miele L, Xu K. Targeting Met and Notch in the Lfng-deficient, Met-amplified triple-negative breast cancer. Cancer Biol Ther. 15, 633-42 (2014)
PubMed link      E-mail link

Reference Number: 1661
Koh YW, Lee HJ, Ahn JH, Lee JW, Gong G. MET expression is associated with disease-specific survival in breast cancer patients in the neoadjuvant setting. Pathol Res Pract. 210, 494-500 (2014)
PubMed link      E-mail link

Reference Number: 1668
Gao Y, Zeng F, Wu JY, Li HY, Fan JJ, Mai L, Zhang J, Ma DM, Li Y, Song FZ. MiR-335 inhibits migration of breast cancer cells through targeting oncoprotein c-Met. Tumour Biol. 36, 2875-83 (2015)
PubMed link      E-mail link

Reference Number: 1682
Baccelli I, Stenzinger A, Vogel V, Pfitzner BM, Klein C, Wallwiener M, Scharpff M, Saini M, Holland-Letz T, Sinn HP, Schneeweiss A, Denkert C, Weichert W, Trumpp A. Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients. Oncotarget. 5, 8147-60 (2014)
PubMed link      E-mail link

Reference Number: 1683
Mueller KL, Madden JM, Zoratti GL, Kuperwasser C, List K, Boerner JL. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met. Breast Cancer Res. 14, R104 (2012)
PubMed link      E-mail link

Reference Number: 1694
Sasi W, Ye L, Jiang WG, Sharma AK, Mokbel K. In vitro and in vivo effects of suppressor of cytokine signalling 7 knockdown in breast cancer: the influence on cellular response to hepatocyte growth factor. Biomed Res Int. 648040 (2014)
PubMed link      E-mail link

Reference Number: 1732
Akl MR, Ayoub NM, Ebrahim HY, Mohyeldin MM, Orabi KY, Foudah AI, El Sayed KA Araguspongine C induces autophagic death in breast cancer cells through suppression of c-Met and HER2 receptor tyrosine kinase signaling. Mar Drugs. 13, 288-311 (2015)
PubMed link      E-mail link

Reference Number: 1752
Sarkar TR, Battula VL, Werden SJ, Vijay GV, Ramirez-Peña EQ, Taube JH, Chang JT, Miura N, Porter W, Sphyris N, Andreeff M, Mani SA. GD3 synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer. Oncogene. 34, 2958-67 (2015)
PubMed link      E-mail link

Reference Number: 1847
Sueta A, Yamamoto Y, Yamamoto-Ibusuki M, Hayashi M, Takeshita T, Yamamoto S, Omoto Y, Iwase H. Differential role of MACC1 expression and its regulation of the HGF/c Met pathway between breast and colorectal cancer. Int J Oncol. 46, 2143-53 (2015)
PubMed link      E-mail link

Reference Number: 1848
Liu S, Meric-Bernstam F, Parinyanitikul N, Wang B, Eterovic AK, Zheng X, Gagea M, Chavez-MacGregor M, Ueno NT, Lei X, Zhou W, Nair L, Tripathy D, Brown PH, Hortobagyi GN, Chen K, Mendelsohn J, Mills GB, Gonzalez-Angulo AM. Functional consequence of the MET-T1010I polymorphism in breast cancer. Oncotarget. 6, 2604-14 (2015)
PubMed link      E-mail link

Reference Number: 1873
Yi YW, You K, Bae EJ, Kwak SJ, Seong YS, Bae I. Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6. Int J Oncol. 47, 122-32 (2015)
PubMed link      E-mail link

Reference Number: 1874
Yan S, Jiao X, Zou H, Li K. Prognostic significance of c-Met in breast cancer: a meta-analysis of 6010 cases. Diagn Pathol. 10, 62 (2015)
PubMed link      E-mail link

Reference Number: 1893
Hung TH, Li YH, Tseng CP, Lan YW, Hsu SC, Chen YH, Huang TT, Lai HC, Chen CM, Choo KB, Chong KY. Knockdown of c-MET induced apoptosis in ABCB1-overexpressed multidrug-resistance cancer cell lines. Cancer Gene Ther. 22, 262-70 (2015)
PubMed link      E-mail link

Cervical

Reference Number: 29
Baykal, C., Ayhan, A., Al, A. & Yuce, K. Overexpression of the c-Met/HGF receptor and its prognostic significance in uterine cervix carcinomas. Gynecol Oncol 88, 123-9. (2003).
PubMed link      E-mail link

Reference Number: 238
Hudelist G, Czerwenka K, Singer C, Pischinger K, Kubista E, Manavi M. cDNA array analysis of cytobrush-collected normal and malignant cervical epithelial cells: a feasibility study. Cancer Genet Cytogenet. 158, 35-42 (2005)
PubMed link      E-mail link

Reference Number: 239
Walker F, Kermorgant S, Darai E, Madelenat P, Cremieux AC, Henin D, Lehy T. Hepatocyte growth factor and c-Met in cervical intraepithelial neoplasia: overexpression of proteins associated with oncogenic human papillomavirus and human immunodeficiency virus. Clin Cancer Res 9:273-84 (2003).
PubMed link      E-mail link

Reference Number: 398
Tsai HW, Chow NH, Lin CP, Chan SH, Chou CY, Ho CL. The significance of prohibitin and c-Met/hepatocyte growth factor receptor in the progression of cervical adenocarcinoma. Hum Pathol. 37, 198-204. Epub 2005 Dec 20 (2006)
PubMed link      E-mail link

Reference Number: 466
Leo C, Horn LC, Einenkel J, Hentschel B, Hockel M. Tumor hypoxia and expression of c-met in cervical cancer. Gynecol Oncol. 104, 181-5 (2007)
PubMed link      E-mail link

Reference Number: 624
Lee WY, Huang SC, Hsu KF, Tzeng CC, Shen WL. Roles for hypoxia-regulated genes during cervical carcinogenesis: somatic evolution during the hypoxia-glycolysis-acidosis sequence. Gynecol Oncol. 108, 377-84 (2008)
PubMed link      E-mail link

Reference Number: 1179
Chen TC, Hung YC, Lin TY, Chang HW, Chiang IP, Chen YY, Chow KC. Human papillomavirus infection and expression of ATPase family AAA domain containing 3A, a novel anti-autophagy factor, in uterine cervical cancer. Int J Mol Med. 28, 689-96 (2011)
PubMed link      E-mail link

Reference Number: 1232
Horn LC, Hommel N, Roschlau U, Bilek K, Hentschel B, Einenkel J. Peritumoral stromal remodeling, pattern of invasion and expression of c-met/HGF in advanced squamous cell carcinoma of the cervix uteri, FIGO stages III and IV. Eur J Obstet Gynecol Reprod Biol. 163, 76-80 (2012)
PubMed link      E-mail link

Reference Number: 1269
Comunoglu C, Boynukalin K, Ugur MG, Al R, Kuzey GM, Baykal C. Overexpression of c-Met in cervical intraepithelial neoplasia. Eur J Gynaecol Oncol. 33, 625-8 (2012)
PubMed link      E-mail link

Reference Number: 1365
Kim BW1, Cho H, Chung JY, Conway C, Ylaya K, Kim JH, Hewitt SM. Prognostic assessment of hypoxia and metabolic markers in cervical cancer using automated digital image analysis of immunohistochemistry. J Transl Med. 11, 185 (2013)
PubMed link      E-mail link

Reference Number: 1762
Zhuang XP, Jin WW, Teng XD, Yuan ZZ, Lin QQ, Xu ST. c-Met and RON expression levels in endometrial adenocarcinoma tissue and their relationship with prognosis. Eur J Gynaecol Oncol. 36, 255-9 (2015)
PubMed link      E-mail link

Reference Number: 1838
Miekus K, Pawlowska M, Sekula M, Drabik G, Madeja Z, Adamek D, Majka M MET receptor is a potential therapeutic target in high grade cervical cancer. Oncotarget. 6, 10086-101 (2015)
PubMed link      E-mail link

Cholangiocarcinoma

Reference Number: 305
Aishima SI, Taguchi KI, Sugimachi K, Shimada M, Sugimachi K, Tsuneyoshi M. c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. Histopathology 40, 269-78 (2002)
PubMed link      E-mail link

Reference Number: 470
Leelawat K, Leelawat S, Tepaksorn P, Rattanasinganchan P, Leungchaweng A, Tohtong R, Sobhon P. Involvement of c-Met/hepatocyte growth factor pathway in cholangiocarcinoma cell invasion and its therapeutic inhibition with small interfering RNA specific for c-Met. J Surg Res. 136, 78-84 (2006)
PubMed link      E-mail link

Reference Number: 473
Farazi PA, Zeisberg M, Glickman J, Zhang Y, Kalluri R, DePinho RA. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. Cancer Res. 66, 6622-7 (2006)
PubMed link      E-mail link

Reference Number: 1121
Miyamoto M, Ojima H, Iwasaki M, Shimizu H, Kokubu A, Hiraoka N, Kosuge T, Yoshikawa D, Kono T, Furukawa H, Shibata T. Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma. Br J Cancer. 105, 131-8 (2011)
PubMed link      E-mail link

Reference Number: 1244
Dai R, Li J, Fu J, Chen Y, Wang R, Zhao X, Luo T, Zhu J, Ren Y, Cao J, Qian Y, Li N, Wang H. The tyrosine kinase c-Met contributes to the pro-tumorigenic function of the p38 kinase in human bile duct cholangiocarcinoma cells. J Biol Chem. 287, 39812-23 (2012)
PubMed link      E-mail link

Reference Number: 1405
Ge X1, Wang Y, Li Q, Yu H, Ji G, Miao L. NK4 regulates 5-fluorouracil sensitivity in cholangiocarcinoma cells by modulating the intrinsic apoptosis pathway. Oncol Rep. 30, 448-54 (2013)
PubMed link      E-mail link

Reference Number: 1895
Watanabe H, Yokoyama Y, Kokuryo T, Ebata T, Igami T, Sugawara G, Mizuno T, Shimoyama Y, Nagino M. Prognostic Value of Hepatocyte Growth Factor Receptor Expression in Patients with Perihilar Cholangiocarcinoma. Ann Surg Oncol. 22, 2235-42 (2015)
PubMed link      E-mail link

Chronic Myeloid Leukemia

Reference Number: 1208
Kentsis A, Reed C, Rice KL, Sanda T, Rodig SJ, Tholouli E, Christie A, Valk PJ, Delwel R, Ngo V, Kutok JL, Dahlberg SE, Moreau LA, Byers RJ, Christensen JG, Vande Woude G, Licht JD, Kung AL, Staudt LM, Look AT. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat Med. 18, 1118-22 (2012)
PubMed link      E-mail link

Colorectal

Reference Number: 32
Otte, J. M. et al. Functional expression of HGF and its receptor in human colorectal cancer. Digestion 61, 237-46 (2000).
PubMed link      E-mail link

Reference Number: 33
Di Renzo, M. F. et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1, 147-54. (1995).
PubMed link      E-mail link

Reference Number: 34
Fazekas, K., Csuka, O., Koves, I., Raso, E. & Timar, J. Experimental and clinicopathologic studies on the function of the HGF receptor in human colon cancer metastasis. Clin Exp Metastasis 18, 639-49 (2000).
PubMed link      E-mail link

Reference Number: 35
Fujita, S. & Sugano, K. Expression of c-met proto-oncogene in primary colorectal cancer and liver metastases. Jpn J Clin Oncol 27, 378-83. (1997).
PubMed link      E-mail link

Reference Number: 36
Liu, C., Park, M. & Tsao, M. S. Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas. Oncogene 7, 181-5. (1992).
PubMed link      E-mail link

Reference Number: 311
Boon EM, Kovarikova M, Derksen PW, van der Neut R. MET signalling in primary colon epithelial cells leads to increased transformation irrespective of aberrant Wnt signalling. Br J Cancer92, 1078-83 (2005)

PubMed link      E-mail link

Reference Number: 479
Rasola A, Fassetta M, De Bacco F, D'Alessandro L, Gramaglia D, Di Renzo MF, Comoglio PM. A positive feedback loop between hepatocyte growth factor receptor and beta-catenin sustains colorectal cancer cell invasive growth. Oncogene. 26, 1078-87 (2007)
PubMed link      E-mail link

Reference Number: 480
Kammula US, Kuntz EJ, Francone TD, Zeng Z, Shia J, Landmann RG, Paty PB, Weiser MR. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett. 248, 219-28 (2007)
PubMed link      E-mail link

Reference Number: 483
Singh R, Subramanian S, Rhodes JM, Campbell BJ. Peanut lectin stimulates proliferation of colon cancer cells by interaction with glycosylated CD44v6 isoforms and consequential activation of c-Met and MAPK: functional implications for disease-associated glycosylation changes. Glycobiology. 16, 594-601 (2006)
PubMed link      E-mail link

Reference Number: 590
Baldus SE, Kort EJ, Schirmacher P, Dienes HP, Resau JH. Quantification of MET and hepatocyte growth factor/scatter factor expression in colorectal adenomas, carcinomas and non-neoplastic epithelia by quantitative laser scanning microscopy. Int J Oncol. 31, 199-204 (2007)
PubMed link      E-mail link

Reference Number: 625
Seiden-Long I, Navab R, Shih W, Li M, Chow J, Zhu CQ, Radulovich N, Saucier C, Tsao MS. Gab1 but not Grb2 mediates tumor progression in Met overexpressing colorectal cancer cells. Carcinogenesis. 29, 647-55 (2008)
PubMed link      E-mail link

Reference Number: 646
Ginty F, Adak S, Can A, Gerdes M, Larsen M, Cline H, Filkins R, Pang Z, Li Q, Montalto MC. The relative distribution of membranous and cytoplasmic met is a prognostic indicator in stage I and II colon cancer. Clin Cancer Res. 14, 3814-22 (2008)
PubMed link      E-mail link

Reference Number: 647
Lee CT, Chow NH, Su PF, Lin SC, Lin PC, Lee JC. The prognostic significance of RON and MET receptor coexpression in patients with colorectal cancer. Dis Colon Rectum. 51, 1268-74 (2008)
PubMed link      E-mail link

Reference Number: 648
Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H, Carano RA, Kasman I, Mai E, Young J, Zha J, Zhang Z, Ross S, Schwall R, Colbern G, Merchant M. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res. 68, 4360-8 (2008)
PubMed link      E-mail link

Reference Number: 658
Zeng ZS, Weiser MR, Kuntz E, Chen CT, Khan SA, Forslund A, Nash GM, Gimbel M, Yamaguchi Y, Culliford AT 4th, D'Alessio M, Barany F, Paty PB. c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett. 265, 258-69 (2008)
PubMed link      E-mail link

Reference Number: 706
Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner I, Birchmeier W, Schlag PM. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med. 15, 59-67 (2009) Epub 2008 Dec 21
PubMed link      E-mail link

Reference Number: 735
Takeuchi H, Kim J, Fujimoto A, Umetani N, Mori T, Bilchik A, Turner R, Tran A, Kuo C, Hoon DS. X-Linked inhibitor of apoptosis protein expression level in colorectal cancer is regulated by hepatocyte growth factor/C-met pathway via Akt signaling. Clin Cancer Res. 11, 7621-8 (2005)
PubMed link      E-mail link

Reference Number: 799
Nam HJ, Chae S, Jang SH, Cho H, Lee JH. The PI3K-Akt mediates oncogenic Met-induced centrosome amplification and chromosome instability. Carcinogenesis. 31, 1531-40 (2010)
PubMed link      E-mail link

Reference Number: 837
Osada S, Matsui S, Komori S, Yamada J, Sanada Y, Ihawa A, Tanaka Y, Tokuyama Y, Okumura N, Nonaka K, Hosono Y, Takahashi T, Yamaguchi K, Yoshida K. Effect of hepatocyte growth factor on progression of liver metastasis in colorectal cancer. Hepatogastroenterology. 57, 76-80 (2010)
PubMed link      E-mail link

Reference Number: 841
Holgren C, Dougherty U, Edwin F, Cerasi D, Taylor I, Fichera A, Joseph L, Bissonnette M, Khare S. Sprouty-2 controls c-Met expression and metastatic potential of colon cancer cells: sprouty/c-Met upregulation in human colonic adenocarcinomas. Oncogene. 29, 5241-53 (2010)
PubMed link      E-mail link

Reference Number: 876
Moore AE, Greenhough A, Roberts HR, Hicks DJ, Patsos HA, Williams AC, Paraskeva C. HGF/Met signalling promotes PGE(2) biogenesis via regulation of COX-2 and 15-PGDH expression in colorectal cancer cells. Carcinogenesis. 30, 1796-804 (2009)
PubMed link      E-mail link

Reference Number: 878
De Oliveira AT, Matos D, Logullo AF, DA Silva SR, Neto RA, Filho AL, Saad SS. MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality. Anticancer Res. 29, 4807-11 (2009)
PubMed link      E-mail link

Reference Number: 917
Walker F, Abramowitz L, Benabderrahmane D, Duval X, Descatoire V, Hénin D, Lehy T, Aparicio T. Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus. Hum Pathol. 40, 1517-27 (2009)
PubMed link      E-mail link

Reference Number: 931
Takeuchi H, Bilchik A, Saha S, Turner R, Wiese D, Tanaka M, Kuo C, Wang HJ, Hoon DS. c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res. 9, 1480-8 (2003)
PubMed link      E-mail link

Reference Number: 947
Matsui S, Osada S, Tomita H, Komori S, Mori R, Sanada Y, Takahashi T, Yamaguchi K, Yoshida K. Clinical significance of aggressive hepatectomy for colorectal liver metastasis, evaluated from the HGF/c-Met pathway. Int J Oncol. 37, 289-97 (2010)
PubMed link      E-mail link

Reference Number: 965
Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, Kaufman D, Dekoning T, Eagleson B, Buchanan SG, Vande Woude GF. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 70, 6880-90 (2010)
PubMed link      E-mail link

Reference Number: 1035
Qiu J, Huang P, Liu Q, Hong J, Li B, Lu C, Wang L, Wang J, Yuan Y. Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. J Transl Med. 9, 166 (2011)
PubMed link      E-mail link

Reference Number: 1050
Galimi F, Torti D, Sassi F, Isella C, Corà D, Gastaldi S, Ribero D, Muratore A, Massucco P, Siatis D, Paraluppi G, Gonella F, Maione F, Pisacane A, David E, Torchio B, Risio M, Salizzoni M, Capussotti L, Perera T, Medico E, Di Renzo MF, Comoglio PM, Trusolino L, Bertotti A. Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations. Clin Cancer Res. 17, 3146-56 (2011)
PubMed link      E-mail link

Reference Number: 1056
Inno A, Di Salvatore M, Cenci T, Martini M, Orlandi A, Strippoli A, Ferrara AM, Bagalà C, Cassano A, Larocca LM, Barone C. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? Clin Colorectal Cancer. 10, 325-32 (2011)
PubMed link      E-mail link

Reference Number: 1062
Saigusa S, Toiyama Y, Tanaka K, Yokoe T, Fujikawa H, Matsushita K, Okugawa Y, Inoue Y, Uchida K, Mohri Y, Kusunoki M. Inhibition of HGF/cMET expression prevents distant recurrence of rectal cancer after preoperative chemoradiotherapy. Int J Oncol. 40, 583-91 (2012)
PubMed link      E-mail link

Reference Number: 1067
Uddin S, Hussain AR, Ahmed M, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Bavi P, Al-Kuraya KS. Coexpression of activated c-Met and death receptor 5 predicts better survival in colorectal carcinoma. Am J Pathol. 179, 3032-44 (2011)
PubMed link      E-mail link

Reference Number: 1076
van der Horst EH, Chinn L, Wang M, Velilla T, Tran H, Madrona Y, Lam A, Ji M, Hoey TC, Sato AK. Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models in vivo. Neoplasia. 11, 355-64 (2009)
PubMed link      E-mail link

Reference Number: 1113
Neklason DW, Done MW, Sargent NR, Schwartz AG, Anton-Culver H, Griffin CA, Ahnen DJ, Schildkraut JM, Tomlinson GE, Strong LC, Miller AR, Stopfer JE, Burt RW. Activating mutation in MET oncogene in familial colorectal cancer. BMC Cancer. 11, 424 (2011)
PubMed link      E-mail link

Reference Number: 1140
Migliore C, Martin V, Leoni VP, Restivo A, Atzori L, Petrelli A, Isella C, Zorcolo L, Sarotto I, Casula G, Comoglio PM, Columbano A, Giordano S. MiR-1 downregulation cooperates with MACC1 in promoting MET overexpression in human colon cancer. Clin Cancer Res. 18, 737-47 (2012)
PubMed link      E-mail link

Reference Number: 1141
Kawamura M, Saigusa S, Toiyama Y, Tanaka K, Okugawa Y, Hiro J, Uchida K, Mohri Y, Inoue Y, Kusunoki M. Correlation of MACC1 and MET expression in rectal cancer after neoadjuvant chemoradiotherapy. Anticancer Res. 32, 1527-31 (2012)
PubMed link      E-mail link

Reference Number: 1157
Liu Y, Li Q, Zhu L. Expression of the hepatocyte growth factor and c-Met in colon cancer: correlation with clinicopathological features and overall survival. Tumori. 98, 105-12 (2012)
PubMed link      E-mail link

Reference Number: 1290
Voutsina A, Tzardi M, Kalikaki A, Zafeiriou Z, Papadimitraki E, Papadakis M, Mavroudis D, Georgoulias V. Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer. Mod Pathol. 26, 302-13 (2013)
PubMed link      E-mail link

Reference Number: 1295
Siemens H, Neumann J, Jackstadt R, Mansmann U, Horst D, Kirchner T, Hermeking H. Detection of miR-34a promoter methylation in combination with elevated expression of c-Met and ß-catenin predicts distant metastasis of colon cancer. Clin Cancer Res. 219, 710-20 (2013)
PubMed link      E-mail link

Reference Number: 1328
Garouniatis A, Zizi-Sermpetzoglou A, Rizos S, Kostakis A, Nikiteas N, Papavassiliou AG. FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk. Int J Colorectal Dis. 28, 9-18 (2013)
PubMed link      E-mail link

Reference Number: 1344
Zuo Y1, Ren S, Wang M, Liu B, Yang J, Kuai X, Lin C, Zhao D, Tang L, He F. Novel roles of liver sinusoidal endothelial cell lectin in colon carcinoma cell adhesion, migration and in-vivo metastasis to the liver. Gut. 62, 1169-78 (2013)
PubMed link      E-mail link

Reference Number: 1345
Sun YL1, Liu WD, Ma GY, Gao DW, Jiang YZ, Liu Q, Du JJ. Expression of HGF and Met in human tissues of colorectal cancers: biological and clinical implications for synchronous liver metastasis. Int J Med Sci. 10, 548-59 (2013)
PubMed link      E-mail link

Reference Number: 1391
Chen HJ1, Jiang YL, Lin CM, Tsai SC, Peng SF, Fushiya S, Hour MJ, Yang JS. Dual inhibition of EGFR and c-Met kinase activation by MJ-56 reduces metastasis of HT29 human colorectal cancer cells. Int J Oncol. 43, 141-50 (2013)
PubMed link      E-mail link

Reference Number: 1424
Deeb KK1, Sram JP, Gao H, Fakih MG. Multigene assays in metastatic colorectal cancer J Natl Compr Canc Netw. 11 Suppl 4:S9-17 (2013)
PubMed link      E-mail link

Reference Number: 1434
Samamé Pérez-Vargas JC1, Biondani P, Maggi C, Gariboldi M, Gloghini A, Inno A, Volpi CC, Gualeni AV, di Bartolomeo M, de Braud F, Castano A, Bossi I, Pietrantonio F. Role of cMET in the development and progression of colorectal cancer. Int J Mol Sci. 14, 18056-77 (2013)
PubMed link      E-mail link

Reference Number: 1456
Kishiki T, Ohnishi H, Masaki T, Ohtsuka K, Ohkura Y, Furuse J, Watanabe T, Sugiyama M. Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS. Cancer Chemother Pharmacol. 73, 749-57 (2014)
PubMed link      E-mail link

Reference Number: 1462
Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D, Apicella M, Migliardi G, Galimi F, Lauricella C, Zanon C, Perera T, Veronese S, Corti G, Amatu A, Gambacorta M, Diaz LA Jr, Sausen M, Velculescu VE, Comoglio P, Trusolino L, Di Nicolantonio F, Giordano S, Siena S. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 3, 658-73 (2013)
PubMed link      E-mail link

Reference Number: 1471
Hur K, Cejas P, Feliu J, Moreno-Rubio J, Burgos E, Boland CR, Goel A. Hypomethylation of long interspersed nuclear element-1 (LINE-1) leads to activation of proto-oncogenes in human colorectal cancer metastasis. Gut. 63, 635-46 (2014)
PubMed link      E-mail link

Reference Number: 1487
Takeyama H, Yamamoto H, Yamashita S, Wu X, Takahashi H, Nishimura J, Haraguchi N, Miyake Y, Suzuki R, Murata K, Ohue M, Kato T, Takemasa I, Mizushima T, Ishii H, Mimori K, Doki Y, Mori M. Decreased miR-340 expression in bone marrow is associated with liver metastasis of colorectal cancer. Mol Cancer Ther. 13, 976-85 (2014)
PubMed link      E-mail link

Reference Number: 1490
Ren B, Zakharov V, Yang Q, McMahon L, Yu J, Cao W. MACC1 is related to colorectal cancer initiation and early-stage invasive growth. Am J Clin Pathol. 140, 701-7 (2013)
PubMed link      E-mail link

Reference Number: 1521
Luraghi P, Reato G, Cipriano E, Sassi F, Orzan F, Bigatto V, De Bacco F, Menietti E, Han M, Rideout WM 3rd, Perera T, Bertotti A, Trusolino L, Comoglio PM, Boccaccio C. MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. Cancer Res. 74, 1857-69 (2014)
PubMed link      E-mail link

Reference Number: 1551
Boccaccio C, Luraghi P, Comoglio PM. MET-mediated resistance to EGFR inhibitors: an old liaison rooted in colorectal cancer stem cells. Cancer Res. 74, 3647-51 (2014)
PubMed link      E-mail link

Reference Number: 1557
Basilico C, Hultberg A, Blanchetot C, de Jonge N, Festjens E, Hanssens V, Osepa SI, De Boeck G, Mira A, Cazzanti M, Morello V, Dreier T, Saunders M, de Haard H, Michieli P. Four individually druggable MET hotspots mediate HGF-driven tumor progression. J Clin Invest. 124, 3172-86 (2014)
PubMed link      E-mail link

Reference Number: 1561
Apostolou P, Toloudi M, Ioannou E, Kourtidou E, Chatziioannou M, Kopic A, Komiotis D, Kiritsis C, Manta S, Papasotiriou I. Study of the interaction among Notch pathway receptors, correlation with stemness, as well as their interaction with CD44, dipeptidyl peptidase-IV, hepatocyte growth factor receptor and the SETMAR transferase, in colon cancer stem cells. J Recept Signal Transduct Res. 33, 353-8 (2013)
PubMed link      E-mail link

Reference Number: 1562
Troiani T, Martinelli E, Napolitano S, Vitagliano D, Ciuffreda LP, Costantino S, Morgillo F, Capasso A, Sforza V, Nappi A, De Palma R, D'Aiuto E, Berrino L, Bianco R, Ciardiello F. Increased TGF-a as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells. Clin Cancer Res. 19, 6751-65 (2013)
PubMed link      E-mail link

Reference Number: 1585
Shoji H, Yamada Y, Taniguchi H, Nagashima K, Okita N, Takashima A, Honma Y, Iwasa S, Kato K, Hamaguchi T, Shimada Y. Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection. Cancer Sci. 105, 1002-7 (2014)
PubMed link      E-mail link

Reference Number: 1589
Satoh K, Nimura S, Aoki M, Hamasaki M, Koga K, Iwasaki H, Yamashita Y, Kataoka H, Nabeshima K. Tumor budding in colorectal carcinoma assessed by cytokeratin immunostaining and budding areas: possible involvement of c-Met. Cancer Sci. 105, 1487-95 (2014)
PubMed link      E-mail link

Reference Number: 1590
Cougnoux A, Dalmasso G, Martinez R, Buc E, Delmas J, Gibold L, Sauvanet P, Darcha C, Déchelotte P, Bonnet M, Pezet D, Wodrich H, Darfeuille-Michaud A, Bonnet R Bacterial genotoxin colibactin promotes colon tumour growth by inducing a senescence-associated secretory phenotype. Gut. 63, 1932-42 (2014)
PubMed link      E-mail link

Reference Number: 1591
Harpaz N, Taboada S, Ko HM, Yu J, Yang Q, Xu H, Cao W. Expression of MACC1 and MET in inflammatory bowel disease-associated colonic neoplasia. Inflamm Bowel Dis. 20, 703-11 (2014)
PubMed link      E-mail link

Reference Number: 1632
Song N, Liu S, Zhang J, Liu J, Xu L, Liu Y, Qu X. Cetuximab-induced MET activation acts as a novel resistance mechanism in colon cancer cells. Int J Mol Sci. 15, 5838-51 (2014)
PubMed link      E-mail link

Reference Number: 1633
Kishiki T, Ohnishi H, Masaki T, Ohtsuka K, Ohkura Y, Furuse J, Sugiyama M, Watanabe T. Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation. Oncol Rep. 32, 57-64 (2014)
PubMed link      E-mail link

Reference Number: 1666
Li Y, Wang J, Gao X, Han W, Zheng Y, Xu H, Zhang C, He Q, Zhang L, Li Z, Zhou D. c-Met targeting enhances the effect of irradiation and chemical agents against malignant colon cells harboring a KRAS mutation. PLoS One. 9, e113186 (2014)
PubMed link      E-mail link

Reference Number: 1697
Elliott VA, Rychahou P, Zaytseva YY, Evers BM. Activation of c-Met and upregulation of CD44 expression are associated with the metastatic phenotype in the colorectal cancer liver metastasis model. PLoS One. 9(5):e97432 (2014)
PubMed link      E-mail link

Reference Number: 1734
Bigatto V, De Bacco F, Casanova E, Reato G, Lanzetti L, Isella C, Sarotto I, Comoglio PM, Boccaccio C TNF-a promotes invasive growth through the MET signaling pathway. Mol Oncol. 9, 377-88 (2015)
PubMed link      E-mail link

Reference Number: 1761
Li J, Bharadwaj SS, Guzman G, Vishnubhotla R, Glover SC. ROCK I Has More Accurate Prognostic Value than MET in Predicting Patient Survival in Colorectal Cancer. Anticancer Res. 35, 3267-73 (2015)
PubMed link      E-mail link

Reference Number: 1763
Burggraaf J, Kamerling IM, Gordon PB, Schrier L, de Kam M, Kales AJ, Bendiksen R, Indrevoll B, Bjerke RM, Moestue SA, Yazdanfar S, Langers AM, Swaerd-Nordmo M, Torheim G, Warren MV, Morreau H, Voorneveld PW, Buckle T, van Leeuwen FW, Ødegårdstuen LI, Dalsgaard GT, Healey A, Hardwick JC. Detection of colorectal polyps in humans using an intravenously administered fluorescent peptide targeted against c-Met. Nat Med. 21, 955-61 (2015)
PubMed link      E-mail link

Reference Number: 1766
Cui YM, Jiao HL, Ye YP, Chen CM, Wang JX, Tang N, Li TT, Lin J, Qi L, Wu P, Wang SY, He MR, Liang L, Bian XW, Liao WT, Ding YQ. FOXC2 promotes colorectal cancer metastasis by directly targeting MET. Oncogene. 34, 4379-90 (2015)
PubMed link      E-mail link

Reference Number: 1831
Abou-Bakr AA, Elbasmi A. c-MET overexpression as a prognostic biomarker in colorectal adenocarcinoma. Gulf J Oncolog. 1, 28-34 (2013)
PubMed link      E-mail link

Reference Number: 1832
Seo AN, Park KU, Choe G, Kim WH, Kim DW, Kang SB, Lee HS. Clinical and prognostic value of MET gene copy number gain and chromosome 7 polysomy in primary colorectal cancer patients. Tumour Biol. 36, 9813-21 (2015)
PubMed link      E-mail link

Reference Number: 1847
Sueta A, Yamamoto Y, Yamamoto-Ibusuki M, Hayashi M, Takeshita T, Yamamoto S, Omoto Y, Iwase H. Differential role of MACC1 expression and its regulation of the HGF/c Met pathway between breast and colorectal cancer. Int J Oncol. 46, 2143-53 (2015)
PubMed link      E-mail link

Reference Number: 1862
Sclafani F, Rimassa L, Colombo P, Destro A, Stinco S, Lutman FR, Carnaghi C, Beretta G, Zanello A, Roncalli M, Giordano L, Santoro A. An exploratory biomarker study in metastatic tumors from colorectal cancer patients treated with bevacizumab. Int J Biol Markers. 30, e73-80 (2015)
PubMed link      E-mail link

Reference Number: 1892
Liu Z, Wei P, Yang Y, Cui W, Cao B, Tan C, Yu B, Bi R, Xia K, Chen W, Wang Y, Zhang Y, Du X, Zhou X. BATF2 Deficiency Promotes Progression in Human Colorectal Cancer via Activation of HGF/MET Signaling: A Potential Rationale for Combining MET Inhibitors with IFNs. Clin Cancer Res. 21, 1752-63 (2015)
PubMed link      E-mail link

Endometrial

Reference Number: 578
Wagatsuma S, Konno R, Sato S, Yajima A. Tumor angiogenesis, hepatocyte growth factor, and c-Met expression in endometrial carcinoma. Cancer. 82, 520-30 (1998)
PubMed link      E-mail link

Reference Number: 579
Walentinsson A, Helou K, Wallenius V, Hedrich HJ, Szpirer C, Levan G. Independent amplification of two gene clusters on chromosome 4 in rat endometrial cancer: identification and molecular characterization. Cancer Res. 61, 8263-73 (2001)
PubMed link      E-mail link

Reference Number: 580
Bae-Jump V, Segreti EM, Vandermolen D, Kauma S. Hepatocyte growth factor (HGF) induces invasion of endometrial carcinoma cell lines in vitro. Gynecol Oncol. 73, 265-72 (1999)
PubMed link      E-mail link

Reference Number: 581
He Y, Peng Z, Pan X, Wang H, Ouyang Y. Expression and correlation of C-met and estrogen receptor in endometrial carcinomas. Sichuan Da Xue Xue Bao Yi Xue Ban. 34, 78-9 (2003)
PubMed link      E-mail link

Reference Number: 582
O'Toole SA, Dunn E, Sheppard BL, Klocker H, Bektic J, Smyth P, Martin C, Sheils O, O'Leary JJ. Genome-wide analysis of deoxyribonucleic acid in endometrial cancer using comparative genomic hybridization microarrays. Int J Gynecol Cancer. 16, 834-42 (2006)
PubMed link      E-mail link

Reference Number: 604
Samuelson E, Nordlander C, Levan G, Behboudi A. Amplification studies of MET and Cdk6 in a rat endometrial tumor model and their correlation to human type I endometrial carcinoma tumors. Adv Exp Med Biol. 617, 511-7 (2008)
PubMed link      E-mail link

Reference Number: 1655
Thoury A, Descatoire V, Kotelevets L, Kannengiesser C, Bertrand G, Theou-Anton N, Frey C, Genestie C, Raymond E, Chastre E, Lehy T, Walker F. Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability. Histol Histopathol. 29, 1455-66 (2014)
PubMed link      E-mail link

Esophogeal

Reference Number: 40
Saeki, H. et al. Concurrent overexpression of Ets-1 and c-Met correlates with a phenotype of high cellular motility in human esophageal cancer. Int J Cancer 98, 8-13 (2002).
PubMed link      E-mail link

Reference Number: 261
Hu YC, Lam KY, Law S, Wong J, Srivastava G. Profiling of differentially expressed cancer-related genes in esophageal squamous cell carcinoma (ESCC) using human cancer cDNA arrays: overexpression of oncogene MET correlates with tumor differentiation in ESCC. Clin Cancer Res 7:3519-25 (2001).
PubMed link      E-mail link

Reference Number: 262
Porte H, Triboulet JP, Kotelevets L, Carrat F, Prevot S, Nordlinger B, DiGioia Y, Wurtz A, Comoglio P, Gespach C, Chastre E. Overexpression of stromelysin-3, BM-40/SPARC, and MET genes in human esophageal carcinoma: implications for prognosis. Clin Cancer Res 4:1375-82 (1998).
PubMed link      E-mail link

Reference Number: 348
Herrera LJ, El-Hefnawy T, Queiroz de Oliveira PE, Raja S, Finkelstein S, Gooding W, Luketich JD, Godfrey TE, Hughes SJ. The HGF receptor c-Met is overexpressed in esophageal adenocarcinoma. Neoplasia. 7, 75-84 (2005)
PubMed link      E-mail link

Reference Number: 397
Miller CT, Lin L, Casper AM, Lim J, Thomas DG, Orringer MB, Chang AC, Chambers AF, Giordano TJ, Glover TW, Beer DG. Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene. 25, 409-18 (2006)
PubMed link      E-mail link

Reference Number: 405
Tuynman JB, Buskens CJ, Kemper K, ten Kate FJ, Offerhaus GJ, Richel DJ, van Lanschot JJ. Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma. Ann Surg. 242, 840-9 (2005)
PubMed link      E-mail link

Reference Number: 486
Watson GA, Zhang X, Stang MT, Levy RM, Queiroz de Oliveira PE, Gooding WE, Christensen JG, Hughes SJ. Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma. Neoplasia. 8, 949-55 (2006)
PubMed link      E-mail link

Reference Number: 487
Anderson MR, Harrison R, Atherfold PA, Campbell MJ, Darnton SJ, Obszynska J, Jankowski JA. Met receptor signaling: a key effector in esophageal adenocarcinoma. Clin Cancer Res. 12, 5936-43 (2006)
PubMed link      E-mail link

Reference Number: 637
Papineni S, Chintharlapalli S, Abdelrahim M, Lee SO, Burghardt R, Abudayyeh A, Baker C, Herrera L, Safe S. Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. Carcinogenesis. 30, 1193-201 (2009)
PubMed link      E-mail link

Reference Number: 642
Tuynman JB, Lagarde SM, Ten Kate FJ, Richel DJ, van Lanschot JJ. Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma. Br J Cancer. 98, 1102-8 (2008)
PubMed link      E-mail link

Reference Number: 1054
Catenacci DV, Cervantes G, Yala S, Nelson EA, El-Hashani E, Kanteti R, El Dinali M, Hasina R, Brägelmann J, Seiwert T, Sanicola M, Henderson L, Grushko TA, Olopade O, Karrison T, Bang YJ, Kim WH, Tretiakova M, Vokes E, Frank DA, Kindler HL, Huet H, Salgia R. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther. 12, 9-46 (2011)
PubMed link      E-mail link

Reference Number: 1307
Kato H, Arao T, Matsumoto K, Fujita Y, Kimura H, Hayashi H, Nishiki K, Iwama M, Shiraishi O, Yasuda A, Shinkai M, Imano M, Imamoto H, Yasuda T, Okuno K, Shiozaki H, Nishio K. Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma. Int J Oncol. 42, 1151-8 (2013)
PubMed link      E-mail link

Reference Number: 1396
Sano A1, Sakurai S, Kato H, Suzuki S, Yokobori T, Sakai M, Tanaka N, Inose T, Sohda M, Nakajima M, Fukai Y, Miyazaki T, Ojima H, Hosoya Y, Enomoto T, Kanda T, Ajioka Y, Kuwano H. Expression of receptor tyrosine kinases in esophageal carcinosarcoma. Oncol Rep. 29, 2119-26 (2013)
PubMed link      E-mail link

Reference Number: 1420
Dent P. Non-canonical p53 signaling to promote invasion. Cancer Biol Ther. 14, 879-80 (2013)
PubMed link      E-mail link

Reference Number: 1768
Catenacci DV, Liao WL, Thyparambil S, Henderson L, Xu P, Zhao L, Rambo B, Hart J, Xiao SY, Bengali K, Uzzell J, Darfler M, Krizman DB, Cecchi F, Bottaro DP, Karrison T, Veenstra TD, Hembrough T, Burrows J. Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue. PLoS One. 9, e100586 (2014)
PubMed link      E-mail link

Reference Number: 1787
Catenacci DV, Liao WL, Thyparambil S, Henderson L, Xu P, Zhao L, Rambo B, Hart J, Xiao SY, Bengali K, Uzzell J, Darfler M, Krizman DB, Cecchi F, Bottaro DP, Karrison T, Veenstra TD, Hembrough T, Burrows J. Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue. PLoS One. 9, e100586 (2014)
PubMed link      E-mail link

Reference Number: 1858
Xu Y, Peng Z, Li Z, Lu M, Gao J, Li Y, Li Y, Shen L. Expression and clinical significance of c-Met in advanced esophageal squamous cell carcinoma. BMC Cancer. 15, 6 (2015)
PubMed link      E-mail link

Reference Number: 1869
Ozawa Y, Nakamura Y, Fujishima F, Felizola SJ, Takeda K, Okamoto H, Ito K, Ishida H, Konno T, Kamei T, Miyata G, Ohuchi N, Sasano H. c-Met in esophageal squamous cell carcinoma: an independent prognostic factor and potential therapeutic target. BMC Cancer. 15, 451 (2015)
PubMed link      E-mail link

Gastric

Reference Number: 41
Wu, C. W. et al. Hepatocyte growth factor and Met/HGF receptors in patients with gastric adenocarcinoma. Oncol Rep 5, 817-22. (1998).
PubMed link      E-mail link

Reference Number: 42
Amemiya, H. et al. c-Met expression in gastric cancer with liver metastasis. Oncology 63, 286-96 (2002).
PubMed link      E-mail link

Reference Number: 43
Nakajima, M. et al. The prognostic significance of amplification and overexpression of c- met and c-erb B-2 in human gastric carcinomas. Cancer 85, 1894-902. (1999).
PubMed link      E-mail link

Reference Number: 44
Taniguchi, K. et al. The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor. Cancer 82, 2112-22 (1998).
PubMed link      E-mail link

Reference Number: 243
Churin Y, Al-Ghoul L, Kepp O, Meyer TF, Birchmeier W, Naumann M. Helicobacter pylori CagA protein targets the c-Met receptor and enhances the motogenic response. J Cell Biol 161:249-55 (2003).
PubMed link      E-mail link

Reference Number: 315
Wang JY, Hsieh JS, Chen CC, Tzou WS, Cheng TL, Chen FM, Huang TJ, Huang YS, Huang SY, Yang T, Lin SR. Alterations of APC, c-met, and p53 genes in tumor tissue and serum of patients with gastric cancers. J Surg Res 120, 242-8 (2004)
PubMed link      E-mail link

Reference Number: 317
Amemiya H, Kono K, Takahashi A, Kamei S, Sugai H, Ichihara F, Fujii H, Matsumoto Y. c-Met expression in a gastric cancer cell line producing alpha-fetoprotein. Surg Today 34, 115-22 (2004)
PubMed link      E-mail link

Reference Number: 318
Tang Z, Zhao M, Ji J, Yang G, Hu F, He J, Shen H, Gao Z, Zhao A, Li J, Lu Y. Overexpression of gastrin and c-met protein involved in human gastric carcinomas and intestinal metaplasia. Oncol Rep 11, 333-9 (2004)
PubMed link      E-mail link

Reference Number: 327
Inoue T, Kataoka H, Goto K, Nagaike K, Igami K, Naka D, Kitamura N, Miyazawa K. Activation of c-Met (hepatocyte growth factor receptor) in human gastric cancer tissue. Cancer Sci. 95, 803-8 (2004)
PubMed link      E-mail link

Reference Number: 361
Yamashita H, Kitayama J, Shida D, Ishikawa M, Hama K, Aoki J, Arai H, Nagawa H. Differential expression of lysophosphatidic acid receptor-2 in intestinal and diffuse type gastric cancer. J Surg Oncol. 93, 30-5 (2006)
PubMed link      E-mail link

Reference Number: 396
Drebber U, Baldus SE, Nolden B, Grass G, Bollschweiler E, Dienes HP, Hölscher AH, Mönig SP. The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation. Oncol Rep. 19, 1477-83 (2008)
PubMed link      E-mail link

Reference Number: 488
Luo B, Wang Y, Wang XF, Gao Y, Huang BH, Zhao P. Correlation of Epstein-Barr virus and its encoded proteins with Helicobacter pylori and expression of c-met and c-myc in gastric carcinoma. World J Gastroenterol. 12, 1842-8 (2006)
PubMed link      E-mail link

Reference Number: 891
Chen JH, Wu CW, Kao HL, Chang HM, Li AF, Liu TY, Chi CW. Effects of COX-2 inhibitor on growth of human gastric cancer cells and its relation to hepatocyte growth factor. Cancer Lett. 239, 263-70 (2006)
PubMed link      E-mail link

Reference Number: 897
Lee KH, Choi EY, Hyun MS, Jang BI, Kim TN, Kim SW, Song SK, Kim JH, Kim JR. Hepatocyte growth factor/c-met signaling in regulating urokinase plasminogen activator in human stomach cancer: A potential therapeutic target for human stomach cancer. Korean J Intern Med. 21, 20-7 (2006)
PubMed link      E-mail link

Reference Number: 948
Bertotti A, Bracco C, Girolami F, Torti D, Gastaldi S, Galimi F, Medico E, Elvin P, Comoglio PM, Trusolino L. Inhibition of Src impairs the growth of met-addicted gastric tumors. Clin Cancer Res. 16, 3933-43 (2010)
PubMed link      E-mail link

Reference Number: 949
Cepero V, Sierra JR, Corso S, Ghiso E, Casorzo L, Perera T, Comoglio PM, Giordano S. MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res. 70, 7580-90 (2010)
PubMed link      E-mail link

Reference Number: 965
Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, Kaufman D, Dekoning T, Eagleson B, Buchanan SG, Vande Woude GF. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 70, 6880-90 (2010)
PubMed link      E-mail link

Reference Number: 974
Lee J, Seo JW, Jun HJ, Ki CS, Park SH, Park YS, Lim HY, Choi MG, Bae JM, Sohn TS, Noh JH, Kim S, Jang HL, Kim JY, Kim KM, Kang WK, Park JO. Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep. 25, 1517-24 (2011)
PubMed link      E-mail link

Reference Number: 1072
Okamoto W, Okamoto I, Arao T, Yanagihara K, Nishio K, Nakagawa K. Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells. Br J Cancer. 105, 407-12 (2011)
PubMed link      E-mail link

Reference Number: 1073
Kitamura S, Miyazaki Y, Hiraoka S, Toyota M, Nagasawa Y, Kondo S, Kiyohara T, Shinomura Y, Matsuzawa Y. PPARgamma inhibits the expression of c-MET in human gastric cancer cells through the suppression of Ets. Biochem Biophys Res Commun. 265, 453-6 (1999)
PubMed link      E-mail link

Reference Number: 1119
Zhao J, Zhang X, Xin Y. Up-regulated expression of Ezrin and c-Met proteins are related to the metastasis and prognosis of gastric carcinomas. Histol Histopathol. 26, 1111-20 (2011)
PubMed link      E-mail link

Reference Number: 1124
Janjigian YY, Tang LH, Coit DG, Kelsen DP, Francone TD, Weiser MR, Jhanwar SC, Shah MA. MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev. 20, 1021-7 (2011)
PubMed link      E-mail link

Reference Number: 1145
Toiyama Y, Yasuda H, Saigusa S, Matushita K, Fujikawa H, Tanaka K, Mohri Y, Inoue Y, Goel A, Kusunoki M. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer. Int J Cancer. 130, 2912-21 (2012)
PubMed link      E-mail link

Reference Number: 1203
Wang XL, Chen XM, Fang JP, Yang CQ. Lentivirus-mediated RNA silencing of c-Met markedly suppresses peritoneal dissemination of gastric cancer in vitro and in vivo. Acta Pharmacol Sin. 33, 513-22 (2012)
PubMed link      E-mail link

Reference Number: 1205
Chen CT, Kim H, Liska D, Gao S, Christensen JG, Weiser MR. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells. Mol Cancer Ther. 11, 660-9 (2012)
PubMed link      E-mail link

Reference Number: 1218
Li Y, Chen CQ, He YL, Cai SR, Yang DJ, He WL, Xu JB, Zan WH. Abnormal expression of E-cadherin in tumor cells is associated with poor prognosis of gastric carcinoma. J Surg Oncol. 106, 304-10 (2012)
PubMed link      E-mail link

Reference Number: 1225
Sotoudeh K, Hashemi F, Madjd Z, Sadeghipour A, Molanaei S, Kalantary E. The clinicopathologic association of c-MET overexpression in Iranian gastric carcinomas; an immunohistochemical study of tissue microarrays. Diagn Pathol. 7, 57 (2012)
PubMed link      E-mail link

Reference Number: 1226
Lee HE, Kim MA, Lee HS, Jung EJ, Yang HK, Lee BL, Bang YJ, Kim WH. MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer. 107, 325-33 (2012)
PubMed link      E-mail link

Reference Number: 1261
Hong SW, Jung KH, Park BH, Zheng HM, Lee HS, Choi MJ, Yun JI, Kang NS, Lee J, Hong SS. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer. Cancer Lett. 332, 74-82 (2013)
PubMed link      E-mail link

Reference Number: 1334
Lee J, Lee SE, Kang SY, Do IG, Lee S, Ha SY, Cho J, Kang WK, Jang J, Ou SH, Kim KM. Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer. 119, 1627-35 (2013)
PubMed link      E-mail link

Reference Number: 1406
Yashiro M1, Nishii T, Hasegawa T, Matsuzaki T, Morisaki T, Fukuoka T, Hirakawa K. A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma. Br J Cancer 109, 2619-28 (2013)
PubMed link      E-mail link

Reference Number: 1407
Gomes C1, Osório H, Pinto MT, Campos D, Oliveira MJ, Reis CA. Expression of ST3GAL4 leads to SLe(x) expression and induces c-Met activation and an invasive phenotype in gastric carcinoma cells. PLoS One. 8, e66737 (2013)
PubMed link      E-mail link

Reference Number: 1422
Liu YJ, Shen D, Yin X, Gavine P, Zhang T, Su X, Zhan P, Xu Y, Lv J, Qian J, Liu C, Sun Y, Qian Z, Zhang J, Gu Y, Ni X. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma. Br J Cancer. 110, 1169-78 (2014)
PubMed link      E-mail link

Reference Number: 1453
Yamaguchi H1, Takanashi M, Yoshida N, Ito Y, Kamata R, Fukami K, Yanagihara K, Sakai R. Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors. Cancer Sci. 105, 528-36 (2014)
PubMed link      E-mail link

Reference Number: 1498
Kang BW, Lee D, Chung HY, Han JH, Kim YB. Tetraspanin CD151 expression associated with prognosis for patients with advanced gastric cancer. J Cancer Res Clin Oncol. 139, 1835-43 (2013)
PubMed link      E-mail link

Reference Number: 1528
Ma J, Ma J, Meng Q, Zhao ZS, Xu WJ. Prognostic value and clinical pathology of MACC-1 and c-MET expression in gastric carcinoma. Pathol Oncol Res. 19, 821-32 (2013)
PubMed link      E-mail link

Reference Number: 1563
Wu JG, Yu JW, Wu HB, Zheng LH, Ni XC, Li XQ, Du GY, Jiang BJ. Expressions and clinical significances of c-MET, p-MET and E2f-1 in human gastric carcinoma. BMC Res Notes. 7, 6 (2014)
PubMed link      E-mail link

Reference Number: 1566
Ha SY, Lee J, Kang SY, Do IG, Ahn S, Park JO, Kang WK, Choi MG, Sohn TS, Bae JM, Kim S, Kim M, Kim S, Park CK, Ignatius Ou SH, Kim KM. MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas. Mod Pathol. 26, 1632-41 (2013)
PubMed link      E-mail link

Reference Number: 1584
Ha SY, Do IG, Lee J, Park SH, Park JO, Kang WK, Choi MG, Lee JH, Bae JM, Kim S, Kim KM, Sohn TS. CD151 overexpression is associated with poor prognosis in patients with pT3 gastric cancer. Ann Surg Oncol. 21, 1099-106 (2014)
PubMed link      E-mail link

Reference Number: 1595
Peng Y, Guo JJ, Liu YM, Wu XL MicroRNA-34A inhibits the growth, invasion and metastasis of gastric cancer by targeting PDGFR and MET expression. Biosci Rep. 34 (3) (2014)
PubMed link      E-mail link

Reference Number: 1617
Meng L, Shu M, Chen Y, Yang D, He Q, Zhao H, Feng Z, Liang C, Yu K. A novel lead compound CM-118: antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers. Cancer Biol Ther. 15, 721-34 (2014)
PubMed link      E-mail link

Reference Number: 1626
Liu H, Qian C, Shen Z. Anti-tumor activity of oridonin on SNU-5 subcutaneous xenograft model via regulation of c-Met pathway. Tumour Biol. 35, 9139-46 (2014)
PubMed link      E-mail link

Reference Number: 1654
Zhang Z, Wang J, Ji D, Wang C, Liu R, Wu Z, Liu L, Zhu D, Chang J, Geng R, Xiong L, Fang Q, Li J. Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer. Clin Cancer Res. 20, 4559-73 (2014)
PubMed link      E-mail link

Reference Number: 1680
Zhang L, Xia L, Zhao L, Chen Z, Shang X, Xin J, Liu M, Guo X, Wu K, Pan Y, Fan D. Activation of PAX3-MET pathways due to miR-206 loss promotes gastric cancer metastasis. Carcinogenesis. 36, 390-9 (2015)
PubMed link      E-mail link

Reference Number: 1714
Sun L, Duan J, Jiang Y, Wang L, Huang N, Lin L, Liao Y, Liao W Metastasis-associated in colon cancer-1 upregulates vascular endothelial growth factor-C/D to promote lymphangiogenesis in human gastric cancer. Cancer Lett. 357, 242-53 (2015)
PubMed link      E-mail link

Reference Number: 1718
Ha SY, Lee J, Jang J, Hong JY, Do IG, Park SH, Park JO, Choi MG, Sohn TS, Bae JM, Kim S, Kim M, Kim S, Park CK, Kang WK, Kim KM. HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy. Int J Cancer. 136, 1629-35 (2015)
PubMed link      E-mail link

Reference Number: 1727
Kurokawa Y, Matsuura N, Kawabata R, Nishikawa K, Ebisui C, Yokoyama Y, Shaker MN, Hamakawa T, Takahashi T, Takiguchi S, Mori M, Doki Y. Prognostic impact of major receptor tyrosine kinase expression in gastric cancer. Ann Surg Oncol. 21 Suppl 4, S584-90 (2014)
PubMed link      E-mail link

Reference Number: 1740
Choi J, Lee HE, Kim MA, Jang BG, Lee HS, Kim WH. Analysis of MET mRNA expression in gastric cancers using RNA in situ hybridization assay: its clinical implication and comparison with immunohistochemistry and silver in situ hybridization. PLoS One. 9, e111658 (2014)
PubMed link      E-mail link

Reference Number: 1741
Petti C, Picco G, Martelli ML, Trisolini E, Bucci E, Perera T, Isella C, Medico E. Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells. Oncotarget. 6, 221-33 (2015)
PubMed link      E-mail link

Reference Number: 1784
Ma JA, Hu C, Li W, Ren J, Zou F, Zhou D, Zou W, Wei Y, Zhou Y. Downregulation of c-Met expression does not enhance the sensitivity of gastric cancer cell line MKN-45 to gefitinib. Mol Med Rep. 11, 2269-75 (2015)
PubMed link      E-mail link

Reference Number: 1785
Heindl S, Eggenstein E, Keller S, Kneissl J, Keller G, Mutze K, Rauser S, Gasteiger G, Drexler I, Hapfelmeier A, Höfler H, Luber B. Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines. J Cancer Res Clin Oncol. 138, 843-58 (2012)
PubMed link      E-mail link

Reference Number: 1810
Liu J, Xue H, Zhang J, Suo T, Xiang Y, Zhang W, Ma J, Cai D, Gu X. MicroRNA-144 inhibits the metastasis of gastric cancer by targeting MET expression. J Exp Clin Cancer Res. 34, 35 (2015)
PubMed link      E-mail link

Reference Number: 1811
Zhu C, Xu J, Li M, Zhao G, Cao H. Heterogeneity of c-Met expression in Chinese gastric cancer patients. Hum Pathol. 46, 1901-7 (2015)
PubMed link      E-mail link

Reference Number: 1813
Noguchi E, Saito N, Kobayashi M, Kameoka S. Clinical significance of hepatocyte growth factor/c-Met expression in the assessment of gastric cancer progression. Mol Med Rep. 11, 3423-31 (2015)
PubMed link      E-mail link

Reference Number: 1839
Zheng Z, Yan D, Chen X, Huang H, Chen K, Li G, Zhou L, Zheng D, Tu L, Dong XD. MicroRNA-206: Effective Inhibition of Gastric Cancer Progression through the c-Met Pathway. PLoS One. 10, e0128751 (2015)
PubMed link      E-mail link

Reference Number: 1853
Wu Z, Wang H, Fang S, Xu C. MiR-449c inhibits gastric carcinoma growth. Life Sci. 137, 14-9 (2015)
PubMed link      E-mail link

Reference Number: 1876
Kim ST, Do IG, Lee J, Sohn I, Kim KM, Kang WK. The NanoString-based multigene assay as a novel platform to screen EGFR, HER2, and MET in patients with advanced gastric cancer. Clin Transl Oncol. 17, 462-8 (2015)
PubMed link      E-mail link

Reference Number: 1881
Koch C, Trojan J. Established and Potential Predictive Biomarkers in Gastrointestinal Cancer--c-Kit, Her2, Ras and Beyond. Digestion. 91, 294-302 (2015)
PubMed link      E-mail link

Glioblastomas/Astrocytomas

Reference Number: 186
Koochekpour, S. et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 57, 5391-8 (1997).
PubMed link      E-mail link

Reference Number: 187
Kunkel, P. et al. Expression and localization of scatter factor/hepatocyte growth factor in human astrocytomas. Neuro-oncol 3, 82-8 (2001).
PubMed link      E-mail link

Reference Number: 188
Lamszus, K., Laterra, J., Westphal, M. & Rosen, E. M. Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas. Int J Dev Neurosci 17, 517-30 (1999).
PubMed link      E-mail link

Reference Number: 189
Moriyama, T., Kataoka, H., Koono, M. & Wakisaka, S. Expression of hepatocyte growth factor/scatter factor and its receptor c-Met in brain tumors: evidence for a role in progression of astrocytic tumors (Review). Int J Mol Med 3, 531-6 (1999).
PubMed link      E-mail link

Reference Number: 190
Hirose, Y. et al. Immunohistochemical examination of c-Met protein expression in astrocytic tumors. Acta Neuropathol (Berl) 95, 345-51. (1998).
PubMed link      E-mail link

Reference Number: 191
Nabeshima, K. et al. Expression of c-Met correlates with grade of malignancy in human astrocytic tumours: an immunohistochemical study. Histopathology 31, 436-43. (1997).
PubMed link      E-mail link

Reference Number: 519
Ma Y, Yuan RQ, Fan S, Hu C, Goldberg ID, Laterra JJ, Rosen EM. Identification of genes that modulate sensitivity of U373MG glioblastoma cells to cis-platinum. Anticancer Drugs. 17, 733-51 (2006)
PubMed link      E-mail link

Reference Number: 542
Eckerich C, Zapf S, Fillbrandt R, Loges S, Westphal M, Lamszus K. Hypoxia can induce c-Met expression in glioma cells and enhance SF/HGF-induced cell migration. Int J Cancer. 121, 276-83 (2007)
PubMed link      E-mail link

Reference Number: 622
Tseng JR, Kang KW, Dandekar M, Yaghoubi S, Lee JH, Christensen JG, Muir S, Vincent PW, Michaud NR, Gambhir SS. Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET. J Nucl Med. 49, 129-34 (2008)
PubMed link      E-mail link

Reference Number: 695
Kong DS, Song SY, Kim DH, Joo KM, Yoo JS, Koh JS, Dong SM, Suh YL, Lee JI, Park K, Kim JH, Nam DH. Prognostic significance of c-Met expression in glioblastomas. Cancer. 115, 140-8 (2009)
PubMed link      E-mail link

Reference Number: 730
Kongkham PN, Northcott PA, Ra YS, Nakahara Y, Mainprize TG, Croul SE, Smith CA, Taylor MD, Rutka JT. An epigenetic genome-wide screen identifies SPINT2 as a novel tumor suppressor gene in pediatric medulloblastoma. Cancer Res. 68, 9945-53 (2008)
PubMed link      E-mail link

Reference Number: 731
Knudsen BS, Zhao P, Resau J, Cottingham S, Gherardi E, Xu E, Berghuis B, Daugherty J, Grabinski T, Toro J, Giambernardi T, Skinner RS, Gross M, Hudson E, Kort E, Lengyel E, Ventura A, West RA, Xie Q, Hay R, Woude GV, Cao B. A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings. Appl Immunohistochem Mol Morphol. 17, 57-67 (2009)
PubMed link      E-mail link

Reference Number: 866
Pei Z, Sun P, Huang P, Lal B, Laterra J, Watkins PA. Acyl-CoA synthetase VL3 knockdown inhibits human glioma cell proliferation and tumorigenicity. Cancer Res. 69, 9175-82 (2009)
PubMed link      E-mail link

Reference Number: 940
Liu W, Fu Y, Xu S, Ding F, Zhao G, Zhang K, Du C, Pang B, Pang Q. c-Met expression is associated with time to recurrence in patients with glioblastoma multiforme. J Clin Neurosci. 18, 119-21 (2011)
PubMed link      E-mail link

Reference Number: 1060
Xie Q, Bradley R, Kang L, Koeman J, Ascierto ML, Worschech A, De Giorgi V, Wang E, Kefene L, Su Y, Essenburg C, Kaufman DW, DeKoning T, Enter MA, O'Rourke TJ, Marincola FM, Vande Woude GF. Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. Proc Natl Acad Sci U S A. 109, 570-5 (2012)
PubMed link      E-mail link

Reference Number: 1190
Jun HJ, Acquaviva J, Chi D, Lessard J, Zhu H, Woolfenden S, Bronson RT, Pfannl R, White F, Housman DE, Iyer L, Whittaker CA, Boskovitz A, Raval A, Charest A. Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme. Oncogene. 31, 3039-50 (2012)
PubMed link      E-mail link

Reference Number: 1215
Joo KM, Jin J, Kim E, Ho Kim K, Kim Y, Gu Kang B, Kang YJ, Lathia JD, Cheong KH, Song PH, Kim H, Seol HJ, Kong DS, Lee JI, Rich JN, Lee J, Nam DH. MET signaling regulates glioblastoma stem cells. Cancer Res. 72, 3828-38 (2012)
PubMed link      E-mail link

Reference Number: 1221
De Bacco F, Casanova E, Medico E, Pellegatta S, Orzan F, Albano R, Luraghi P, Reato G, D'Ambrosio A, Porrati P, Patanè M, Maderna E, Pollo B, Comoglio PM, Finocchiaro G, Boccaccio C. The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Res. 72, 4537-50 (2012)
PubMed link      E-mail link

Reference Number: 1263
Galavotti S, Bartesaghi S, Faccenda D, Shaked-Rabi M, Sanzone S, McEvoy A, Dinsdale D, Condorelli F, Brandner S, Campanella M, Grose R, Jones C, Salomoni P. The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells. Oncogene. 32, 699-712 (2013)
PubMed link      E-mail link

Reference Number: 1268
Yang H, Lee HW, Kim Y, Lee Y, Choi YS, Kim KH, Jin J, Lee J, Joo KM, Nam DH. Radiosensitization of brain metastasis by targeting c-MET. Lab Invest. 93, 344-53 (2013)
PubMed link      E-mail link

Reference Number: 1275
Miekus K, Kijowski J, Sekula M, Majka M. 17AEP-GA, an HSP90 antagonist, is a potent inhibitor of glioblastoma cell proliferation, survival, migration and invasion. Oncol Rep. 28, 1903-9 (2012)
PubMed link      E-mail link

Reference Number: 1329
Kim KH, Seol HJ, Kim EH, Rheey J, Jin HJ, Lee Y, Joo KM, Lee J, Nam DH. Wnt/ß-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells. Neuro Oncol. 15, 161-71 (2013)
PubMed link      E-mail link

Reference Number: 1350
Jahangiri A1, De Lay M, Miller LM, Carbonell WS, Hu YL, Lu K, Tom MW, Paquette J, Tokuyasu TA, Tsao S, Marshall R, Perry A, Bjorgan KM, Chaumeil MM, Ronen SM, Bergers G, Aghi MK. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res. 19, 1773-83 (2013)
PubMed link      E-mail link

Reference Number: 1410
Lee SJ1, Seol HJ, Lee HW, Kang WY, Kang BG, Jin J, Jo MY, Jin Y, Lee JI, Joo KM, Nam DH. Gene silencing of c-Met leads to brain metastasis inhibitory effects. Clin Exp Metastasis. 30, 845-54 (2013)
PubMed link      E-mail link

Reference Number: 1423
Murray DW1, Didier S2, Chan A2, Paulino V3, Van Aelst L4, Ruggieri R2, Tran NL3, Byrne AT5, Symons M2. Guanine nucleotide exchange factor Dock7 mediates HGF-induced glioblastoma cell invasion via Rac activation. Br J Cancer. 110, 1307-15 (2014)
PubMed link      E-mail link

Reference Number: 1469
Byeon SJ, Cho HJ, Baek HW, Park CK, Choi SH, Kim SH, Kim HK, Park SH. Rhabdoid glioblastoma is distinguishable from classical glioblastoma by cytogenetics and molecular genetics. Hum Pathol. 45, 611-20 (2014)
PubMed link      E-mail link

Reference Number: 1544
Jun HJ, Bronson RT, Charest A. Inhibition of EGFR induces a c-MET-driven stem cell population in glioblastoma. Stem Cells. 32, 338-48 (2013)
PubMed link      E-mail link

Reference Number: 1556
Olmez OF, Cubukcu E, Evrensel T, Kurt M, Avci N, Tolunay S, Bekar A, Deligonul A, Hartavi M, Alkis N, Manavoglu O. The immunohistochemical expression of c-Met is an independent predictor of survival in patients with glioblastoma multiforme. Clin Transl Oncol. 16, 173-7 (2014)
PubMed link      E-mail link

Reference Number: 1557
Basilico C, Hultberg A, Blanchetot C, de Jonge N, Festjens E, Hanssens V, Osepa SI, De Boeck G, Mira A, Cazzanti M, Morello V, Dreier T, Saunders M, de Haard H, Michieli P. Four individually druggable MET hotspots mediate HGF-driven tumor progression. J Clin Invest. 124, 3172-86 (2014)
PubMed link      E-mail link

Reference Number: 1648
Camacho CV, Todorova PK, Hardebeck MC, Tomimatsu N, Gil del Alcazar CR, Ilcheva M, Mukherjee B, McEllin B, Vemireddy V, Hatanpaa K, Story MD, Habib AA, Murty VV, Bachoo R, Burma S. DNA double-strand breaks cooperate with loss of Ink4 and Arf tumor suppressors to generate glioblastomas with frequent Met amplification. Oncogene. 34, 1064-72 (2015)
PubMed link      E-mail link

Reference Number: 1703
Furcht CM, Buonato JM, Skuli N, Mathew LK, Muñoz Rojas AR, Simon MC, Lazzara MJ. Multivariate signaling regulation by SHP2 differentially controls proliferation and therapeutic response in glioma cells. J Cell Sci. 127(Pt 16), 3555-67 (2014)
PubMed link      E-mail link

Reference Number: 1710
Luo H, Hong H, Slater MR, Graves SA, Shi S, Yang Y, Nickles RJ, Fan F, Cai W PET of c-Met in Cancer with 64Cu-Labeled Hepatocyte Growth Factor. J Nucl Med. 56, 758-63 (2015)
PubMed link      E-mail link

Reference Number: 1748
Wang X, Huang X, Yang Z, Gallego-Perez D, Ma J, Zhao X, Xie J, Nakano I, Lee LJ. Targeted delivery of tumor suppressor microRNA-1 by transferrin-conjugated lipopolyplex nanoparticles to patient-derived glioblastoma stem cells. Curr Pharm Biotechnol. 15, 839-46 (2014)
PubMed link      E-mail link

Reference Number: 1894
Lee JS, Oh E, Yoo JY, Choi KS, Yoon MJ, Yun CO. Adenovirus expressing dual c-Met-specific shRNA exhibits potent antitumor effect through autophagic cell death accompanied by senescence-like phenotypes in glioblastoma cells. Oncotarget. 6, 4051-65 (2015)
PubMed link      E-mail link

Head and Neck

Reference Number: 50
Marshall, D. D. & Kornberg, L. J. Overexpression of scatter factor and its receptor (c-met) in oral squamous cell carcinoma. Laryngoscope 108, 1413-7 (1998).
PubMed link      E-mail link

Reference Number: 52
Aebersold, D. M. et al. Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of Bcl-xL in the resistance of oropharyngeal cancer to ionizing radiation. Int J Cancer 96, 41-54 (2001).
PubMed link      E-mail link

Reference Number: 53
Cortesina, G. et al. Staging of head and neck squamous cell carcinoma using the MET oncogene product as marker of tumor cells in lymph node metastases. Int J Cancer 89, 286-92. (2000).
PubMed link      E-mail link

Reference Number: 54
Galeazzi, E. et al. Detection of MET oncogene/hepatocyte growth factor receptor in lymph node metastases from head and neck squamous cell carcinomas. Eur Arch Otorhinolaryngol 254 Suppl 1, S138-43 (1997).
PubMed link      E-mail link

Reference Number: 55
Morello, S. et al. MET receptor is overexpressed but not mutated in oral squamous cell carcinomas. J Cell Physiol 189, 285-90 (2001).
PubMed link      E-mail link

Reference Number: 56
Sawatsubashi, M., Sasatomi, E., Mizokami, H., Tokunaga, O. & Shin, T. Expression of c-Met in laryngeal carcinoma. Virchows Arch 432, 331-5 (1998).
PubMed link      E-mail link

Reference Number: 260
Suzuki K, Cheng J, Watanabe Y. Hepatocyte growth factor and c-Met (HGF/c-Met) in adenoid cystic carcinoma of the human salivary gland. J Oral Pathol Med 32:84-9 (2003).
PubMed link      E-mail link

Reference Number: 484
Kim CH, Moon SK, Bae JH, Lee JH, Han JH, Kim K, Choi EC. Expression of hepatocyte growth factor and c-Met in hypopharyngeal squamous cell carcinoma. Acta Otolaryngol. 126, 88-94 (2006)
PubMed link      E-mail link

Reference Number: 489
Lo Muzio L, Farina A, Coccia E, Capogreco M, Colella G, Leonardi R, Campisi G, Carinci F. Effect of c-Met expression on survival in head and neck squamous cell carcinoma. Tumour Biol. 27, 115-21 (2006)
PubMed link      E-mail link

Reference Number: 512
Hara S, Nakashiro K, Klosek SK, Ishikawa T, Shintani S, Hamakawa H. Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1alpha in human salivary gland cancer cells. Oral Oncol. 42, 593-8 (2006)
PubMed link      E-mail link

Reference Number: 537
Endo K, Shirai A, Furukawa M, Yoshizaki T. Prognostic value of cell motility activation factors in patients with tongue squamous cell carcinoma. Hum Pathol. 37, 1111-6 (2006)
PubMed link      E-mail link

Reference Number: 655
Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, Lerner EC, Seethala RR, Suzuki S, Quesnelle KM, Morgan S, Ferris RL, Grandis JR, Siegfried JM. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res. 15, 3740-50 (2009)
PubMed link      E-mail link

Reference Number: 667
Perk LR, Stigter-van Walsum M, Visser GW, Kloet RW, Vosjan MJ, Leemans CR, Giaccone G, Albano R, Comoglio PM, van Dongen GA. Quantitative PET imaging of Met-expressing human cancer xenografts with (89)Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging. 2008 May 20. [Epub ahead of print]
PubMed link      E-mail link

Reference Number: 834
Cai KM, Bao XL, Kong XH, Jinag W, Mao MR, Chu JS, Huang YJ, Zhao XJ. Hsa-miR-34c suppresses growth and invasion of human laryngeal carcinoma cells via targeting c-Met. Int J Mol Med. 25, 565-71 (2010)
PubMed link      E-mail link

Reference Number: 907
Brusevold IJ, Søland TM, Khuu C, Christoffersen T, Bryne M. Nuclear and cytoplasmic expression of Met in oral squamous cell carcinoma and in an organotypic oral cancer model. Eur J Oral Sci. 118, 342-9 (2010)
PubMed link      E-mail link

Reference Number: 935
Kim CH, Koh YW, Han JH, Kim JW, Lee JS, Baek SJ, Hwang HS, Choi EC. c-Met expression as an indicator of survival outcome in patients with oral tongue carcinoma. Head Neck. 32, 1655-64 (2010)
PubMed link      E-mail link

Reference Number: 968
Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, Salgia R. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 69, 3021-31 (2009)
PubMed link      E-mail link

Reference Number: 988
Sen B, Peng S, Saigal B, Williams MD, Johnson FM. Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer. Clin Cancer Res. 17, 514-24 (2011)
PubMed link      E-mail link

Reference Number: 1012
Qian CN, Guo X, Cao B, Kort EJ, Lee CC, Chen J, Wang LM, Mai WY, Min HQ, Hong MH, Vande Woude GF, Resau JH, Teh BT. Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res. 62, 589-96 (2002)
PubMed link      E-mail link

Reference Number: 1046
Sun S, Wang Z. Head neck squamous cell carcinoma c-Met? cells display cancer stem cell properties and are responsible for cisplatin-resistance and metastasis. Int J Cancer. 129, 2337-48 (2011)
PubMed link      E-mail link

Reference Number: 1100
Zhao D, Wang SH, Feng Y, Hua CG, Zhao J, Tang XF. Intratumoral c-Met expression is associated with vascular endothelial growth factor C expression, lymphangiogenesis, and lymph node metastasis in oral squamous cell carcinoma: implications for use as a prognostic marker. Hum Pathol. 42, 1514-23 (2011)
PubMed link      E-mail link

Reference Number: 1303
Lim YC, Han JH, Kang HJ, Kim YS, Lee BH, Choi EC, Kim CH. Overexpression of c-Met promotes invasion and metastasis of small oral tongue carcinoma. Oral Oncol. 48, 1114-9 (2012)
PubMed link      E-mail link

Reference Number: 1339
Stabile LP, He G, Lui VW, Thomas S, Henry C, Gubish CT, Joyce S, Quesnelle KM, Siegfried JM, Grandis JR. c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met. Clin Cancer Res. 19, 380-92 (2013)
PubMed link      E-mail link

Reference Number: 1354
Perisanidis C1, Wrba F, Brandstetter A, Kornek G, Mitchell D, Seemann R, Selzer E, Ewers R, Filipits M. Impact of epidermal growth factor receptor, mesenchymal-epithelial transition factor, and insulin-like growth factor receptor 1 expression on survival of patients with oral and oropharyngeal cancer. Br J Oral Maxillofac Surg. 51, 234-40 (2013)
PubMed link      E-mail link

Reference Number: 1383
Kumai T1, Matsuda Y, Oikawa K, Aoki N, Kimura S, Harabuchi Y, Celis E, Kobayashi H. EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy. Br J Cancer. 109, 2155-66 (2013)
PubMed link      E-mail link

Reference Number: 1419
Akervall J1, Nandalur S2, Zhang J3, Qian CN3, Goldstein N4, Gyllerup P5, Gardinger Y5, Alm J5, Lorenc K5, Nilsson K5, Resau J3, Wilson G2, Teh B3 A novel panel of biomarkers predicts radioresistance in patients with squamous cell carcinoma of the head and neck. Eur J Cancer. 50, 570-81 (2014)
PubMed link      E-mail link

Reference Number: 1518
Rajamoorthi A1, Shrivastava S, Steele R, Nerurkar P, Gonzalez JG, Crawford S, Varvares M, Ray RB. Bitter melon reduces head and neck squamous cell carcinoma growth by targeting c-Met signaling. PLoS One. 8, e78006 (2013)
PubMed link      E-mail link

Reference Number: 1530
Zhou Y, Zhao C, Gery S, Braunstein GD, Okamoto R, Alvarez R, Miles SA, Doan NB, Said JW, Gu J, Phillip Koeffler H. Off-target effects of c-MET inhibitors on thyroid cancer cells. Mol Cancer Ther. 13, 134-43 (2014)
PubMed link      E-mail link

Reference Number: 1531
Tao X, Hill KS, Gaziova I, Sastry SK, Qui S, Szaniszlo P, Fennewald S, Resto VA, Elferink LA. Silencing Met receptor tyrosine kinase signaling decreased oral tumor growth and increased survival of nude mice. Oral Oncol. 50, 104-12 (2014)
PubMed link      E-mail link

Reference Number: 1586
Ettl T, Gosau M, Brockhoff G, Schwarz-Furlan S, Agaimy A, Reichert TE, Rohrmeier C, Zenk J, Iro H. Predictors of cervical lymph node metastasis in salivary gland cancer. Head Neck. 36, 517-23 (2014)
PubMed link      E-mail link

Reference Number: 1611
Koo BS, Kim JM, Seo ST, Yoon YH, Kwon KR, Kim SH, Kwon HW, Bae WJ, Lim YC. Upregulation of HGF and c-MET is associated with subclinical central lymph node metastasis in papillary thyroid microcarcinoma. Ann Surg Oncol. 21, 2310-7 (2014)
PubMed link      E-mail link

Reference Number: 1700
Lee BS, Kang S, Kim KA, Song YJ, Cheong KH, Cha HY, Kim CH. Met degradation by SAIT301, a Met monoclonal antibody, reduces the invasion and migration of nasopharyngeal cancer cells via inhibition of EGR-1 expression. Cell Death Dis. 5:e1159 (2014)
PubMed link      E-mail link

Reference Number: 1701
Grugan KD, Vega ME, Wong GS, Diehl JA, Bass AJ, Wong KK, Nakagawa H, Rustgi AK. A common p53 mutation (R175H) activates c-Met receptor tyrosine kinase to enhance tumor cell invasion. Cancer Biol Ther. 14, 853-9 (2013)
PubMed link      E-mail link

Reference Number: 1769
Nisa L, Aebersold DM, Giger R, Zimmer Y, Medová M. Biological, diagnostic and therapeutic relevance of the MET receptor signaling in head and neck cancer. Pharmacol Ther. 143, 337-49 (2014)
PubMed link      E-mail link

Reference Number: 1804
Vasconcelos AC, Wagner VP, Meurer L, Vargas PA, de Souza LB, Fonseca FP, Squarize CH, Castilho RM, Martins MD. Immunoprofile of c-MET/PI3K signaling in human salivary gland tumors. Oral Surg Oral Med Oral Pathol Oral Radiol. 120, 238-47 (2015)
PubMed link      E-mail link

Reference Number: 1849
Ettl T, Viale-Bouroncle S, Hautmann MG, Gosau M, Kölbl O, Reichert TE, Morsczeck C. AKT and MET signalling mediates antiapoptotic radioresistance in head neck cancer cell lines. Oral Oncol. 51, 158-63 (2015)
PubMed link      E-mail link

Reference Number: 1877
Bell D, Ferrarotto R, Fox MD, Roberts D, Hanna EY, Weber RS, El-Naggar AK. Analysis and significance of c-MET expression in adenoid cystic carcinoma of the salivary gland. Cancer Biol Ther. 16, 834-8 (2015)
PubMed link      E-mail link

Reference Number: 1889
Ozawa Y, Nakamura Y, Fujishima F, Felizola SJ, Takeda K, Okamoto H, Ito K, Ishida H, Konno T, Kamei T, Miyata G, Ohuchi N, Sasano H. c-Met in esophageal squamous cell carcinoma: an independent prognostic factor and potential therapeutic target. BMC Cancer. 15, 451 (2015)
PubMed link      E-mail link

Kaposi's Sarcoma

Reference Number: 156
Maier JA, Mariotti M, Albini A, Comi P, Prat M, Comogilio PM, Soria MR. Over-expression of hepatocyte growth factor in human Kaposi's sarcoma. Int J Cancer. 65, 168-72 (1996)
PubMed link      E-mail link

Reference Number: 157
Polverini, P. J. & Nickoloff, B. J. Role of scatter factor and the c-met protooncogene in the pathogenesis of AIDS-associated Kaposi's sarcoma. Adv Cancer Res 66, 235-53 (1995).
PubMed link      E-mail link

Reference Number: 158
Puig, L. et al. Differential expression of c-Met in Kaposi's sarcoma according to progression stage and HIV infection status. J Cutan Pathol 26, 227-31 (1999).
PubMed link      E-mail link

Reference Number: 407
Bardelli C, Sala M, Cavallazzi U, Prat M. Agonist Met antibodies define the signalling threshold required for a full mitogenic and invasive program of Kaposi's Sarcoma cells. Biochem Biophys Res Commun. 334, 1172-9 (2005)
PubMed link      E-mail link

Reference Number: 408
Montaldo F, Maffe A, Morini M, Noonan D, Giordano S, Albini A, Prat M. Expression of functional tyrosine kinases on immortalized Kaposi's sarcoma cells. J Cell Physiol.  184, 246-54 (2000)
PubMed link      E-mail link

Reference Number: 409
Maier J, Mariotti M, Comoglio PM, Soria MR. Interleukin 1 induces an autocrine loop hepatocyte growth factor/c-Met in murine Kaposi-like spindle cells. Oncogene. 13, 1009-15 (1996)

PubMed link      E-mail link

Reference Number: 494
Puig L, Fernández-Figueras MT, Penín RM, Esquius M, Alomar A, Ariza A. Differential expression of c-Met in Kaposi's sarcoma according to progression stage and HIV infection status. J Cutan Pathol. 26, 227-31 (1999)
PubMed link      E-mail link

Kidney

Reference Number: 60
Oh, R. R. et al. Expression of HGF/SF and Met protein is associated with genetic alterations of VHL gene in primary renal cell carcinomas. Apmis 110, 229-38 (2002).
PubMed link      E-mail link

Reference Number: 61
Inoue, K. et al. Overexpression of c-met proto-oncogene associated with chromophilic renal cell carcinoma with papillary growth. Virchows Arch 433, 511-5 (1998).
PubMed link      E-mail link

Reference Number: 62
Nakopoulou, L. et al. Immunodetection of c-met-oncogene's protein product in renal cell neoplasia. Pathol Res Pract 193, 299-304 (1997).
PubMed link      E-mail link

Reference Number: 258
Sweeney P, El-Naggar AK, Lin SH, Pisters LL. Biological significance of c-met over expression in papillary renal cell carcinoma. J Urol 168:51-5 (2002).
PubMed link      E-mail link

Reference Number: 286
Konda R, Sato H, Hatafuku F, Nozawa T, Ioritani N, Fujioka T. Expression of hepatocyte growth factor and its receptor C-met in acquired renal cystic disease associated with renal cell carcinoma. J Urol 171, 2166-70 (2004)
PubMed link      E-mail link

Reference Number: 492
Miyata Y, Kanetake H, Kanda S. Presence of phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor progression and survival in patients with conventional renal cell carcinoma. Clin Cancer Res. 12, 4876-81 (2006)
PubMed link      E-mail link

Reference Number: 493
Choi JS, Kim MK, Seo JW, Choi YL, Kim DH, Chun YK, Ko YH. MET expression in sporadic renal cell carcinomas. J Korean Med Sci. 21, 672-7 (2006)
PubMed link      E-mail link

Reference Number: 495
Nakaigawa N, Yao M, Baba M, Kato S, Kishida T, Hattori K, Nagashima Y, Kubota Y. Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma. Cancer Res. 66, 3699-705 (2006)
PubMed link      E-mail link

Reference Number: 539
Betsunoh H, Mukai S, Akiyama Y, Fukushima T, Minamiguchi N, Hasui Y, Osada Y, Kataoka H. Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma. Cancer Sci. 98, 491-8 (2007)
PubMed link      E-mail link

Reference Number: 634
Bellon SF, Kaplan-Lefko P, Yang Y, Zhang Y, Moriguchi J, Rex K, Johnson CW, Rose PE, Long AM, O'Connor AB, Gu Y, Coxon A, Kim TS, Tasker A, Burgess TL, Dussault I. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem. 283, 2675-83 (2008)
PubMed link      E-mail link

Reference Number: 638
Salvi A, Marchina E, Benetti A, Grigolato P, De Petro G, Barlati S. Germline and somatic c-met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients. Int J Oncol. 33, 271-6 (2008)
PubMed link      E-mail link

Reference Number: 732
Vuononvirta R, Sebire NJ, Messahel B, Perusinghe N, Reis-Filho JS, Pritchard-Jones K, Vujanic GM, Jones C. Expression of hepatocyte growth factor and its receptor met in Wilms' tumors and nephrogenic rests reflects their roles in kidney development. Clin Cancer Res. 15, 2723-30 (2009)
PubMed link      E-mail link

Reference Number: 965
Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, Kaufman D, Dekoning T, Eagleson B, Buchanan SG, Vande Woude GF. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 70, 6880-90 (2010)
PubMed link      E-mail link

Reference Number: 998
Nagi FM, Omar AA, Mostafa MG, Mohammed EA, Abd-Elwahed Hussein MR. The expression pattern of Von Hippel-Lindau tumor suppressor protein, MET proto-oncogene, and TFE3 transcription factor oncoprotein in renal cell carcinoma in Upper Egypt. Ultrastruct Pathol. 35, 79-86 (2011)
PubMed link      E-mail link

Reference Number: 1003
Looyenga BD, Furge KA, Dykema KJ, Koeman J, Swiatek PJ, Giordano TJ, West AB, Resau JH, Teh BT, MacKeigan JP. Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas. Proc Natl Acad Sci U S A. 108, 1439-44 (2011)
PubMed link      E-mail link

Reference Number: 1022
Koochekpour S, Jeffers M, Wang PH, Gong C, Taylor GA, Roessler LM, Stearman R, Vasselli JR, Stetler-Stevenson WG, Kaelin WG Jr, Linehan WM, Klausner RD, Gnarra JR, Vande Woude GF. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol. 19, 5902-12 (1999)
PubMed link      E-mail link

Reference Number: 1336
Gibney GT, Aziz SA, Camp RL, Conrad P, Schwartz BE, Chen CR, Kelly WK, Kluger HM. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol. 24, 343-9 (2013)
PubMed link      E-mail link

Reference Number: 1374
Xia QY, Rao Q, Shen Q, Shi SS, Li L, Liu B, Zhang J, Wang YF, Shi QL, Wang JD, Ma HH, Lu ZF, Yu B, Zhang RS, Zhou XJ. Oncocytic papillary renal cell carcinoma: a clinicopathological study emphasizing distinct morphology, extended immunohistochemical profile and cytogenetic features. Int J Clin Exp Pathol. 6, 1392-9 (2013)
PubMed link      E-mail link

Reference Number: 1379
Ramakrishnan S1, Ellis L, Pili R. Histone modifications: implications in renal cell carcinoma. Epigenomics. 5, 453-62 (2013)
PubMed link      E-mail link

Reference Number: 1549
Huang J, Dong B, Zhang J, Kong W, Chen Y, Xue W, Liu D, Huang Y. miR-199a-3p inhibits hepatocyte growth factor/c-Met signaling in renal cancer carcinoma. Tumour Biol. 35, 5833-43 (2014)
PubMed link      E-mail link

Reference Number: 1699
Balan M, Mier y Teran E, Waaga-Gasser AM, Gasser M, Choueiri TK, Freeman G, Pal S. Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression. J Biol Chem. 290, 8110-20 (2015)
PubMed link      E-mail link

Reference Number: 1754
Mukai S, Yorita K, Kawagoe Y, Katayama Y, Nakahara K, Kamibeppu T, Sugie S, Tukino H, Kamoto T, Kataoka H Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis.Hum Cell. 28, 44-50 (2015)
PubMed link      E-mail link

Reference Number: 1865
Golovine K, Makhov P, Naito S, Raiyani H, Tomaszewski J, Mehrazin R, Tulin A, Kutikov A, Uzzo RG, Kolenko VM. Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma. Cancer Biol Ther. 16, 743-9 (2015)
PubMed link      E-mail link

Leiomyosarcoma

Reference Number: 114
Jeffers, M., Rong, S. & Vande Woude, G. F. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network. Mol Cell Biol 16, 1115-25 (1996).
PubMed link      E-mail link

Reference Number: 138
Rong, S. et al. Met expression and sarcoma tumorigenicity. Cancer Res 53, 5355-60 (1993).
PubMed link      E-mail link

Reference Number: 353
Jiao Y, Zhao P, Zhu J, Grabinski T, Feng Z, Guan X, Skinner RS, Gross MD, Hay RV, Tachibana H, Cao B. Construction of human naive Fab library and characterization of anti-met Fab fragment generated from the library. Mol Biotechnol. 31, 41-54 (2005)
PubMed link      E-mail link

Reference Number: 354
Lee CC, Putnam AJ, Miranti CK, Gustafson M, Wang LM, Vande Woude GF, Gao CF. Overexpression of sprouty 2 inhibits HGF/SF-mediated cell growth, invasion, migration, and cytokinesis. Oncogene 23, 5193-202 (2004)
PubMed link      E-mail link

Reference Number: 355
Zhang YW, Wang LM, Jove R, Vande Woude GF. Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene 21, 217-26 (2002)
PubMed link      E-mail link

Reference Number: 356
Xiao GH, Jeffers M, Bellacosa A, Mitsuuchi Y, Vande Woude GF, Testa JR. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci USA 98, 247-52 (2001)
PubMed link      E-mail link

Reference Number: 640
Zhao P, Grabinski T, Gao C, Skinner RS, Giambernardi T, Su Y, Hudson E, Resau J, Gross M, Vande Woude GF, Hay R, Cao B. Identification of a met-binding peptide from a phage display library. Clin Cancer Res. 13, 6049-55 (2007)
PubMed link      E-mail link

Liver

Reference Number: 72
Kiss, A., Wang, N. J., Xie, J. P. & Thorgeirsson, S. S. Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res 3, 1059-66 (1997).
PubMed link      E-mail link

Reference Number: 73
Ljubimova, J. Y., Petrovic, L. M., Wilson, S. E., Geller, S. A. & Demetriou, A. A. Expression of HGF, its receptor c-met, c-myc, and albumin in cirrhotic and neoplastic human liver tissue. J Histochem Cytochem 45, 79-87 (1997).
PubMed link      E-mail link

Reference Number: 74
Schoedel, K. E., Tyner, V. Z., Kim, T. H., Michalopoulos, G. K. & Mars, W. M. HGF, MET, and Matrix-Related Proteases in Hepatocellular Carcinoma, Fibrolamellar Variant, Cirrhotic and Normal Liver. Mod Pathol 16, 14-21 (2003).
PubMed link      E-mail link

Reference Number: 75
Selden, C. et al. Expression of hepatocyte growth factor mRNA, and c-met mRNA (hepatocyte growth factor receptor) in human liver tumours. J Hepatol 21, 227-34 (1994).
PubMed link      E-mail link

Reference Number: 76
Ueki, T., Fujimoto, J., Suzuki, T., Yamamoto, H. & Okamoto, E. Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology 25, 619-23 (1997).
PubMed link      E-mail link

Reference Number: 403
Zhang SZ, Pan FY, Xu JF, Yuan J, Guo SY, Dai G, Xue B, Shen WG, Wen CJ, Zhao DH, Li CJ. Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol Cancer Ther. 4, 1577-84 (2005)
PubMed link      E-mail link

Reference Number: 449
Ranganathan S, Tan X, Monga SP. beta-Catenin and met deregulation in childhood Hepatoblastomas. Pediatr Dev Pathol.  8, 435-47 (2005)
PubMed link      E-mail link

Reference Number: 450
Osada S, Kanematsu M, Imai H, Goshima S, Sugiyama Y. Evaluation of extracellular signal regulated kinase expression and its relation to treatment of hepatocellular carcinoma. J Am Coll Surg. 201, 405-11 (2005)
PubMed link      E-mail link

Reference Number: 454
Elchuri S, Oberley TD, Qi W, Eisenstein RS, Jackson Roberts L, Van Remmen H, Epstein CJ, Huang TT. CuZnSOD deficiency leads to persistent and widespread oxidative damage and hepatocarcinogenesis later in life. Oncogene. 24, 367-80 (2005)
PubMed link      E-mail link

Reference Number: 468
Yang H, Magilnick N, Noureddin M, Mato JM, Lu SC. Effect of hepatocyte growth factor on methionine adenosyltransferase genes and growth is cell density-dependent in HepG2 cells. J Cell Physiol. 210, 766-73 (2007)
PubMed link      E-mail link

Reference Number: 471
Tward AD, Jones KD, Yant S, Kay MA, Wang R, Bishop JM. Genomic progression in mouse models for liver tumors. Cold Spring Harb Symp Quant Biol. 70, 217-24 (2005)
PubMed link      E-mail link

Reference Number: 476
Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest. 116, 1582-95 (2006)
PubMed link      E-mail link

Reference Number: 477
Wu F, Wu L, Zheng S, Ding W, Teng L, Wang Z, Ma Z, Zhao W. The clinical value of hepatocyte growth factor and its receptor--c-met for liver cancer patients with hepatectomy. Dig Liver Dis. 38, 490-7 (2006)
PubMed link      E-mail link

Reference Number: 611
Tward AD, Jones KD, Yant S, Cheung ST, Fan ST, Chen X, Kay MA, Wang R, Bishop JM. Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci U S A. 104, 14771-6 (2007)
PubMed link      E-mail link

Reference Number: 612
Salvi A, Arici B, Portolani N, Giulini SM, De Petro G, Barlati S. In vitro c-met inhibition by antisense RNA and plasmid-based RNAi down-modulates migration and invasion of hepatocellular carcinoma cells. Int J Oncol. 31, 451-60 (2007)
PubMed link      E-mail link

Reference Number: 632
Takami T, Kaposi-Novak P, Uchida K, Gomez-Quiroz LE, Conner EA, Factor VM, Thorgeirsson SS. Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis. Cancer Res. 67, 9844-51 (2007)
PubMed link      E-mail link

Reference Number: 633
Towner RA, Smith N, Tesiram YA, Abbott A, Saunders D, Blindauer R, Herlea O, Silasi-Mansat R, Lupu F. In vivo detection of c-MET expression in a rat hepatocarcinogenesis model using molecularly targeted magnetic resonance imaging. Mol Imaging. 6, 18-29 (2007)
PubMed link      E-mail link

Reference Number: 645
Lee KH, Choi EY, Hyun MS, Jang BI, Kim TN, Lee HJ, Eun JY, Kim HG, Yoon SS, Lee DS, Kim JH, Kim JR. Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target. Clin Exp Metastasis. 25, 89-96 (2008)
PubMed link      E-mail link

Reference Number: 658
Zeng ZS, Weiser MR, Kuntz E, Chen CT, Khan SA, Forslund A, Nash GM, Gimbel M, Yamaguchi Y, Culliford AT 4th, D'Alessio M, Barany F, Paty PB. c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett. 265, 258-69 (2008)
PubMed link      E-mail link

Reference Number: 681
Chau GY, Lui WY, Chi CW, Chau YP, Li AF, Kao HL, Wu CW. Significance of serum hepatocyte growth factor levels in patients with hepatocellular carcinoma undergoing hepatic resection. Eur J Surg Oncol. 34, 333-8 (2008)
PubMed link      E-mail link

Reference Number: 717
Osada S, Kanematsu M, Imai H, Goshima S. Clinical significance of serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma. Hepatogastroenterology. 55, 544-9 (2008)
PubMed link      E-mail link

Reference Number: 721
Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y, Zheng X. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett. 275, 44-53 Epub 2008 Nov 8. (2009)
PubMed link      E-mail link

Reference Number: 803
Xie B, Xing R, Chen P, Gou Y, Li S, Xiao J, Dong J. Down-regulation of c-Met expression inhibits human HCC cells growth and invasion by RNA interference. J Surg Res. 162, 231-8 (2010)
PubMed link      E-mail link

Reference Number: 900
Singhal G, Rajeswari MR. Interaction of actinomycin D with promoter element of c-met and its inhibitory effect on the expression of c-Met. J Biomol Struct Dyn. 26, 625-36 (2009)
PubMed link      E-mail link

Reference Number: 901
Patil MA, Lee SA, Macias E, Lam ET, Xu C, Jones KD, Ho C, Rodriguez-Puebla M, Chen X. Role of cyclin D1 as a mediator of c-Met- and beta-catenin-induced hepatocarcinogenesis. Cancer Res. 69, 253-61 (2009)
PubMed link      E-mail link

Reference Number: 903
Kaufmann R, Oettel C, Horn A, Halbhuber KJ, Eitner A, Krieg R, Katenkamp K, Henklein P, Westermann M, Böhmer FD, Ramachandran R, Saifeddine M, Hollenberg MD, Settmacher U. Met receptor tyrosine kinase transactivation is involved in proteinase-activated receptor-2-mediated hepatocellular carcinoma cell invasion. Carcinogenesis. 30, 1487-96 (2009)
PubMed link      E-mail link

Reference Number: 909
Marx-Stoelting P, Borowiak M, Knorpp T, Birchmeier C, Buchmann A, Schwarz M. Hepatocarcinogenesis in mice with a conditional knockout of the hepatocyte growth factor receptor c-Met. Int J Cancer. 124, 1767-72 (2009)
PubMed link      E-mail link

Reference Number: 1025
Purcell R, Childs M, Maibach R, Miles C, Turner C, Zimmermann A, Sullivan M. HGF/c-Met related activation of ß-catenin in hepatoblastoma. J Exp Clin Cancer Res. 30:96 (2011)
PubMed link      E-mail link

Reference Number: 1027
Schelter F, Grandl M, Seubert B, Schaten S, Hauser S, Gerg M, Boccaccio C, Comoglio P, Krüger A. Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10. Clin Exp Metastasis. 28, 793-802 (2011)
PubMed link      E-mail link

Reference Number: 1033
Carr BI, Wang Z, Wang M, Cavallini A, D'Alessandro R, Refolo MG. c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition. Cancer Biol Ther. 12, 531-8 (2011)
PubMed link      E-mail link

Reference Number: 1035
Qiu J, Huang P, Liu Q, Hong J, Li B, Lu C, Wang L, Wang J, Yuan Y. Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. J Transl Med. 9, 166 (2011)
PubMed link      E-mail link

Reference Number: 1106
Tan S, Li R, Ding K, Lobie PE, Zhu T. miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway. FEBS Lett. 585, 2229-34 (2011)
PubMed link      E-mail link

Reference Number: 1148
Dai R, Li J, Fu J, Chen Y, Yu L, Zhao X, Qian Y, Zhang H, Chen H, Ren Y, Su B, Luo T, Zhu J, Wang H. Disturbance of Ca2 homeostasis converts pro-Met into non-canonical tyrosine kinase p190MetNC in response to endoplasmic reticulum stress in MHCC97 cells. J Biol Chem. 287, 14586-97 (2012)
PubMed link      E-mail link

Reference Number: 1227
Qu JH, Chang XJ, Lu YY, Bai WL, Chen Y, Zhou L, Zeng Z, Wang CP, An LJ, Hao LY, Xu GL, Gao XD, Lou M, Lv JY, Yang YP. Overexpression of metastasis-associated in colon cancer 1 predicts a poor outcome of hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol. 18, 2995-3003 (2012)